<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Unleashing the power of immune checkpoints: Post-translational modification of novel molecules and clinical applications</title>
				<funder ref="#_W7ubU4a">
					<orgName type="full">Natural Science Foundation of Fujian Province, China</orgName>
				</funder>
				<funder ref="#_fVynwaq #_AZwAXnS #_xp5QW64">
					<orgName type="full">National Natural Science Foundation of China, China</orgName>
				</funder>
				<funder ref="#_CNBsnav">
					<orgName type="full">Fujian Provincial Project of Education and Science for Young and Middle-aged Teachers, China</orgName>
				</funder>
				<funder ref="#_wGkMrvX #_CjdBNPE">
					<orgName type="full">Startup Foundation of Fujian Medical University, China</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2024-02-22">22 February 2024</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Jie</forename><surname>Wang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Pathology</orgName>
								<orgName type="department" key="dep2">Institute of Oncology &amp; Diagnostic Pathology Center</orgName>
								<orgName type="institution" key="instit1">The School of Basic Medical Sciences</orgName>
								<orgName type="institution" key="instit2">Fujian Medical University</orgName>
								<address>
									<settlement>Fuzhou, Fujian</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yian</forename><surname>Wang</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">School of Medicine</orgName>
								<orgName type="department" key="dep2">The Engineering Research Center of Reproduction and Translational Medicine of Hunan Province</orgName>
								<orgName type="laboratory">The Key Laboratory of Model Animals and Stem Cell Biology in Hunan Province</orgName>
								<orgName type="institution">Hunan Normal University</orgName>
								<address>
									<settlement>Changsha, Hunan</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Xianjie</forename><surname>Jiang</surname></persName>
							<affiliation key="aff3">
								<orgName type="laboratory">Hunan Key Laboratory of Cancer Metabolism</orgName>
								<orgName type="institution" key="instit1">Hunan Cancer Hospital</orgName>
								<orgName type="institution" key="instit2">Affiliated Cancer Hospital of Xiangya School of Medicine</orgName>
								<orgName type="institution" key="instit3">Central South University</orgName>
								<address>
									<settlement>Changsha, Hunan</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Meifang</forename><surname>Xu</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Pathology</orgName>
								<orgName type="department" key="dep2">Institute of Oncology &amp; Diagnostic Pathology Center</orgName>
								<orgName type="institution" key="instit1">The School of Basic Medical Sciences</orgName>
								<orgName type="institution" key="instit2">Fujian Medical University</orgName>
								<address>
									<settlement>Fuzhou, Fujian</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Meifeng</forename><surname>Wang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Pathology</orgName>
								<orgName type="department" key="dep2">Institute of Oncology &amp; Diagnostic Pathology Center</orgName>
								<orgName type="institution" key="instit1">The School of Basic Medical Sciences</orgName>
								<orgName type="institution" key="instit2">Fujian Medical University</orgName>
								<address>
									<settlement>Fuzhou, Fujian</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rong</forename><surname>Wang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Pathology</orgName>
								<orgName type="department" key="dep2">Institute of Oncology &amp; Diagnostic Pathology Center</orgName>
								<orgName type="institution" key="instit1">The School of Basic Medical Sciences</orgName>
								<orgName type="institution" key="instit2">Fujian Medical University</orgName>
								<address>
									<settlement>Fuzhou, Fujian</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Boshu</forename><surname>Zheng</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Pathology</orgName>
								<orgName type="department" key="dep2">Institute of Oncology &amp; Diagnostic Pathology Center</orgName>
								<orgName type="institution" key="instit1">The School of Basic Medical Sciences</orgName>
								<orgName type="institution" key="instit2">Fujian Medical University</orgName>
								<address>
									<settlement>Fuzhou, Fujian</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mingfen</forename><surname>Chen</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">The Second Affiliated Hospital of Fujian Medical University</orgName>
								<orgName type="institution" key="instit2">Fujian Medical University</orgName>
								<address>
									<settlement>Quanzhou, Fujian</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Qi</forename><surname>Ke</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Cell Biology and Genetics</orgName>
								<orgName type="institution" key="instit1">The School of Basic Medical Sciences</orgName>
								<orgName type="institution" key="instit2">Fujian Medical University</orgName>
								<address>
									<settlement>Fuzhou, Fujian</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jun</forename><surname>Long</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Shenzhen Geim Graphene Center</orgName>
								<orgName type="department" key="dep2">Shenzhen International Graduate School</orgName>
								<orgName type="institution" key="instit1">Tsinghua-Berkeley Shenzhen Institute &amp; Tsinghua</orgName>
								<orgName type="institution" key="instit2">Tsinghua University</orgName>
								<address>
									<settlement>Shenzhen, Guangdong</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Unleashing the power of immune checkpoints: Post-translational modification of novel molecules and clinical applications</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2024-02-22">22 February 2024</date>
						</imprint>
					</monogr>
					<idno type="MD5">68D635B9C3553C5B0E27177A10DC8C57</idno>
					<idno type="DOI">10.1016/j.canlet.2024.216758</idno>
					<note type="submission">Received 7 November 2023; Received in revised form 15 February 2024; Accepted 21 February 2024</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.0" ident="GROBID" when="2024-06-12T11:40+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>TIM3 LAG3 TIGIT CD47 Post-translational modification</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Immune checkpoint molecules play a pivotal role in the initiation, regulation, and termination of immune responses. Tumor cells exploit these checkpoints to dampen immune cell function, facilitating immune evasion. Clinical interventions target this mechanism by obstructing the binding of immune checkpoints to their ligands, thereby restoring the anti-tumor capabilities of immune cells. Notably, therapies centered on immune checkpoint inhibitors, particularly PD-1/PD-L1 and CTLA-4 blocking antibodies, have demonstrated significant clinical promise. However, a considerable portion of patients still encounter suboptimal efficacy and develop resistance. Recent years have witnessed an exponential surge in preclinical and clinical trials investigating novel immune checkpoint molecules such as TIM3, LAG3, TIGIT, NKG2D, and CD47, along with their respective ligands. The processes governing immune checkpoint molecules, from their synthesis to transmembrane deployment, interaction with ligands, and eventual degradation, are intricately tied to post-translational modifications. These modifications encompass glycosylation, phosphorylation, ubiquitination, neddylation, SUMOylation, palmitoylation, and ectodomain shedding. This discussion proceeds to provide a concise overview of the structural characteristics of several novel immune checkpoints and their ligands. Additionally, it outlines the regulatory mechanisms governed by post-translational modifications, offering insights into their potential clinical applications in immune checkpoint blockade.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Introduction</head><p>Immune checkpoints comprise a series of molecules expressed on the surface of immune cells. They serve as regulators of immune activation, crucial for maintaining autoimmune tolerance and preventing excessive immune system activation. Over recent decades, numerous immune checkpoint molecules have been identified, including but not limited to programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), T cell immunoglobulin domain and mucin domain 3 (TIM3), lymphocyte activation gene 3 (LAG3), T cell immunoreceptor with Ig and ITIM domains (TIGIT), natural killer group 2, member D (NKG2D), and cluster of differentiation 47 (CD47). These molecules form intricate regulatory networks that precisely modulate the type and intensity of immune responses <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref>. Tumor cells can evade immune surveillance by exploiting immune checkpoint pathways to suppress immune responses. However, antibody blockade or recombinant proteins that modulate these pathways can reverse this inhibition, enabling immune cells to re-engage in their cytotoxic functions. Consequently, the blockade of immune checkpoints in treatment has garnered unprecedented attention. Simultaneously, we face challenges and bottlenecks in the development of immunotherapies. Presently, immune checkpoint therapy is primarily employed as a second-line treatment for certain advanced cancers. The current study seeks to ascertain whether improved efficacy and predictive indicators can extend the benefits of immune checkpoint blockade to early-stage anticancer interventions, benefiting a broader patient population. The persistence of drug resistance, encompassing both acquired and natural resistance, stands as a substantial impediment in the landscape of cancer immunotherapy <ref type="bibr" target="#b5">[6]</ref>.</p><p>Following anti-PD-1 and CTLA-4 treatments, patients with diverse tumors, including non-small cell lung cancer (NSCLC), breast cancer, melanoma, ovarian cancer, etc., exhibit an up-regulation of compensatory inhibitory checkpoint signals such as TIM3 and LAG3, leading to acquired drug resistance <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref>. While single-agent treatments with TIM3-blocking antibodies like LY3321367 or sabatolimab <ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref>, and IMP321 (a soluble dimeric recombinant form of LAG3) have shown limited efficacy in advanced solid tumor patients <ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref>, recent research suggests promise. For instance, treatment with TSR-022 (an anti-TIM3 monoclonal antibody) alone resulted in disease stabilization (SD) in 31 melanoma or NSCLC patients and partial responses (PR) in a smooth muscle sarcoma patient with no observed dose-limiting toxicity <ref type="bibr" target="#b18">[19]</ref>. Multiple studies indicate that combining TIM3 or LAG3 inhibitors with PD-1 blockade therapy significantly enhances anti-tumor activity compared to monotherapy, and patients tolerate the combination well <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref>. Notably, the FDA approved Relatlimab, a monoclonal antibody targeting LAG3, in combination with Nivolumab (an anti-PD-1 inhibitor) for treating metastatic melanoma in 2022 <ref type="bibr" target="#b19">[20]</ref>. This emphasizes the potential of combination therapies with novel immune checkpoint blockade in overcoming acquired resistance and improving treatment outcomes in various cancers.</p><p>The limited therapeutic efficacy of various PD-1/PD-L1 immunosuppressants in most solid tumors may be attributed to the reduced infiltration of T cells in solid tumors, accompanied by a high presence of immunosuppressive myeloid cells, resulting in natural resistance <ref type="bibr" target="#b20">[21]</ref>. A promising immunotherapy target on myeloid cells, including macrophages and dendritic cells (DCs), is the CD47/SIRPα pathway, known as the "don't eat me" signal to prevent tumor cells phagocytosis. Recent clinical trials indicate that while CD47 blockade shows good efficacy in several hematological tumors, its therapeutic impact on solid tumors is constrained. However, selective SIRPα blockade demonstrates improved efficacy with milder hematological side effects in solid cancers. The objective response rate (ORR) of SIRPα blockade is notably higher than that of anti-CD47 monoclonal antibody, especially in combination therapy <ref type="bibr" target="#b21">[22]</ref>. These findings suggest that dysfunctional macrophage accumulation in the tumor immune microenvironment might be a key factor in immune escape and non-responsiveness to immunotherapy in solid tumors. Blocking myeloid cells through the CD47-SIRPα axis holds clinical promise for immunotherapy in solid tumors. Researchers also discovered that specific knockout of TIM3 in CD8 + T cells, regulatory T cells (Tregs), or natural killer cells (NK cells) did not significantly affect tumor growth. However, knocking out TIM3 in DCs significantly inhibited tumor growth <ref type="bibr" target="#b22">[23]</ref>. This indicates that, in comparison to T cells, TIM3 on myeloid cells plays a more critical role in tumor immunity by mediating antigen presentation and phagocytosis of apoptotic cells, inhibiting the activation of inflammasomes, and interfering with the stimulator of interferon genes (STING) pathway in DCs <ref type="bibr" target="#b22">[23,</ref><ref type="bibr" target="#b23">24]</ref>. In summary, targeting novel immune checkpoints, especially those related to myeloid cells like SIRPα and TIM3, holds promise for patients who are refractory to conventional immunotherapy approaches.</p><p>Indeed, the intricate mechanisms and biological functions of new immune checkpoint molecules are still areas of active investigation <ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref>. Understanding the protein structure and regulatory mechanisms of these novel immune checkpoints is crucial for improving the efficacy of immune checkpoint inhibitors (ICIs) in patients who are resistant to current therapies. Post-translational modification (PTM) involves the addition or removal of functional groups, proteins, lipids, or sugars from amino acid side chains. This process is catalyzed by various enzymes, including kinases, phosphatases, ligases, and transferases. Alternatively, it can occur through chemical modifications by hydrolases, which cut peptide bonds, removing specific sequences or regulating subunits. This essential regulatory mechanism plays a pivotal role in cell physiological processes, including immune function and tumor pathogenesis. PTM regulates immune checkpoint molecules by modulating their activity, stabilizing protein structures, influencing localization, and mediating interactions with other molecules <ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref>. Despite the challenges associated with studying PTMs, researchers have diligently explored different modifications affecting the expression of immune checkpoint proteins and their ligands. Notably, glycosylation, phosphorylation, ubiquitination, SUMOylation, neddylation, palmitoylation, and ectodomain shedding have been identified as key PTMs in this context <ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref>. Characterizing these post-translational modifications provides valuable insights into novel immune checkpoint molecules, unveiling new targets and therapeutic avenues for cancer immunotherapy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Types of post-translation modification</head><p>Glycosylation is a complex process that the transfer of core glycan from lipid-linked intermediates to peptide receptors in the endoplasmic reticulum (ER) by oligosaccharyltransferase (OST), followed by glycan trimming through Glc removal through glucosidase (GlsIIα/β, GlsI) to fold glycoproteins. Correctly folded proteins are packed for transport to the Golgi apparatus, where a series of ordered modification processes occur, such as polyglycation, fucosylation, galactosylation. Completely folded glycoproteins are recognized by a folding sensor called the glycoprotein glucosyltransferase UGGT1, and glycosylated again. Accumulation of unfolded or incorrectly folded proteins in the endoplasmic reticulum can cause damage and trigger the unfolded protein response (UPR) <ref type="bibr" target="#b35">[36]</ref> (Fig. <ref type="figure" target="#fig_0">1A</ref>). Glycosylation is categorized into two main types: N-glycosylation, which attaches the glycosylation chain to the asparagine residues (-NH2), and O-glycosylation, which links the glycosylation chain to the oxygen atoms of serine, threonine, or hydroxylysine within the polypeptide chain. The N-glycan chains contain a common pentasaccharide core, which is further modified into three major classes of N-glycan chains: high mannose, hybrid, and complex <ref type="bibr" target="#b36">[37]</ref> (Fig. <ref type="figure" target="#fig_0">1A</ref>). The O-glycosylation sites lack a conserved protein signature sequence and exhibit various core structures. While their monosaccharide composition is typically straightforward, their structure is intricate due to the diversity and connectivity of subtypes <ref type="bibr" target="#b37">[38]</ref>. In the tumor microenvironment, factors such as hypoxia and abnormal cellular glycolysis induce extensive and multilevel changes in protein glycosylation patterns, leading to phenomena such as incomplete or abnormally increased glycan synthesis. Glycosylation of immune checkpoint molecules plays a crucial role in enhancing protein stability and thus their half-life in vivo. Additionally, it regulates their interaction with antibodies or ligands and influences protein dimerization <ref type="bibr" target="#b38">[39]</ref>.</p><p>Phosphorylation is a fundamental cellular process involving the transfer of a phosphate group from ATP to amino acid residues of proteins, typically tyrosine or serine/threonine. This enzymatic reaction is catalyzed by protein kinases, and its reverse process involves the removal of the phosphate group by protein phosphatases <ref type="bibr" target="#b39">[40,</ref><ref type="bibr" target="#b40">41]</ref> (Fig. <ref type="figure" target="#fig_0">1B</ref>). In the context of immune checkpoint molecules, tyrosine phosphorylation often serves as a molecular switch, activating downstream signal cascades. On the other hand, serine/threonine phosphorylation is primarily associated with ubiquitin-proteasome-mediated degradation, leading to a reduction in protein expression <ref type="bibr" target="#b31">[32]</ref>.</p><p>Unlike single groups added by phosphorylation modification, ubiquitin (Ub) is a small molecule protein consisting of 76 amino acids and has a highly conserved sequence. The ubiquitination process involves a series of enzymatic steps culminating in the covalent attachment of ubiquitin to a target protein. Initially, ubiquitin is activated in conjunction with ATP by the ubiquitin-activating enzyme E1. Subsequently, the cysteine site of the ubiquitin-conjugating enzyme E2 forms a thioester bond with ubiquitin. The ubiquitin ligase E3 then facilitates the ubiquitination of the substrate by mediating the formation of isopeptide bonds between the carboxyl group of ubiquitin and lysine residues in the substrate. In this cascade of enzymatic reactions, E3 assumes a key role in the specific recognition of target proteins and the regulation of ubiquitination system activity. Depending on the manner of binding, ubiquitination can manifest in different forms: monoubiquitination, where a single ubiquitin molecule is bound to the target protein; multi-ubiquitination, where multiple lysine residues of the target protein are simultaneously labeled by a single ubiquitin molecule; and poly-ubiquitination, where a single lysine residue of the target protein is labeled by multiple ubiquitin molecules <ref type="bibr" target="#b33">[34,</ref><ref type="bibr" target="#b41">42]</ref>. Ubiquitination is a reversible modification, and the deubiquitinating enzyme (DUB) catalyzes the reverse reaction <ref type="bibr" target="#b42">[43]</ref> (Fig. <ref type="figure" target="#fig_0">1C</ref>). Immune checkpoint molecules undergo ubiquitination, marking them for recognition and subsequent degradation by proteasomes <ref type="bibr" target="#b33">[34]</ref>.</p><p>Small ubiquitin-associated modifier (SUMO) and neural precursor cell expressed, developmentally downregulated 8 (NEDD8) are small peptides akin to ubiquitin. Like ubiquitin, their modification process involves corresponding E1, E2, and E3 enzymes, which classifies them under the umbrella term of ubiquitin-like (Ubl) proteins <ref type="bibr" target="#b43">[44]</ref>.</p><p>SUMO encompasses 100 amino acid residues, sharing only 18% sequence similarity with ubiquitin. However, structurally, it closely resembles ubiquitin, featuring the conserved Ub-fold domain at its core <ref type="bibr" target="#b44">[45]</ref>. SUMOylation, the process of adding SUMO to a protein, is dynamic and can be reversed by a specific protease known as SUMO-specific protease (SENP) (Fig. <ref type="figure" target="#fig_0">1D</ref>). NEDD8 comprises 81 amino acid residues and shares a substantial 80% similarity to ubiquitin <ref type="bibr" target="#b43">[44]</ref>. NEDD8 precursors require the action of mature enzymes to cleave the C-terminal end at glycine 76 for it to become functional <ref type="bibr" target="#b45">[46]</ref>. The E1 enzyme responsible for NEDD8 activation is known as the NEDD8-activating enzyme (NAE), which facilitates its attachment to the NEDD8-binding enzyme E2 (UBC12). Subsequently, the NEDD8 ligase E3 is catalyzed to bind with the lysine residue on the target protein. Much like ubiquitination and SUMOylation, neddylation is a reversible process. It can be counteracted by enzymes such as NEDP1, CSN5, and UCH-L3 <ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref> (Fig. <ref type="figure" target="#fig_0">1E</ref>). SUMOylation or Neddylation of a protein can have dual effects. On one hand, it may facilitate proteasomal degradation through the Cullin-RING ligase (CRL) <ref type="bibr" target="#b49">[50,</ref><ref type="bibr" target="#b50">51]</ref>. On the other hand, it can competitively counteract ubiquitination, thereby augmenting protein stability <ref type="bibr" target="#b51">[52]</ref>. Additionally, neddylation has regulatory roles in protein activity or function <ref type="bibr" target="#b52">[53]</ref>.</p><p>Protein palmitoylation involves the Golgi apparatus as the reaction center, where palmitoyl groups are attached to amino acid residues on the side chain of proteins. Its primary form involves S-palmitoylation modification, wherein a 16-carbon fatty acid, palmitic acid, forms a covalent linkage with the cysteine (Cys) residue on protein side chains through an unstable thioester bond <ref type="bibr" target="#b53">[54,</ref><ref type="bibr" target="#b54">55]</ref>. This process is regulated by aspartate-histidine-histidine cysteine (DHHC) palmitoyltransferase and acyl-protein thioesterase (APT) <ref type="bibr" target="#b55">[56]</ref> (Fig. <ref type="figure" target="#fig_0">1F</ref>). Palmitoylation of immune checkpoint molecules stabilizes their protein structure, facilitating efficient transport and localization to the plasma membrane. This process up-regulates their expression on the cell membrane, thereby enhancing their functional activity <ref type="bibr" target="#b30">[31]</ref>.</p><p>Ectodomain shedding, facilitated by proteolytic enzymes such as a disintegrin and metalloproteinases (ADAMs), transforms transmembrane molecules into soluble forms <ref type="bibr" target="#b56">[57]</ref>. In the context of tumor cells, this shedding process may generate ligands for immune activation receptors. By reducing the membrane expression of these ligands, ectodomain shedding functions as a regulatory mechanism. The shed structures serve as bait, binding to corresponding receptors and, consequently, inhibiting the immune activation signal pathway <ref type="bibr" target="#b57">[58]</ref> (Fig. <ref type="figure" target="#fig_0">1G</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Posttranslational modification of TIM3 and its ligands</head><p>TIM3, encoded by the HAVCR2 gene, is a type I membrane protein characterized by distinct structural elements, including a signal peptide (SP), an IgV domain, a mucin domain, a stem region, a transmembrane (TM) domain, and a cytoplasmic region (CR) <ref type="bibr" target="#b58">[59]</ref> (Fig. <ref type="figure" target="#fig_1">2A</ref>). TIM3 is expressed in various immune cell types, encompassing T cells, Tregs, DCs, B cells, macrophages, NK cells, and mast cells.</p><p>TIM3 operates as an immune negative regulator, and the complete understanding of its inhibitory signaling mechanism remains elusive. TIM3 engages with four ligands: Galectin-9 (Gal-9), CEA cell adhesion molecule 1 (CEACAM1), phosphatidylserine (PtdSer) and high mobility family protein B1 (HMGB1) <ref type="bibr" target="#b58">[59]</ref> (Fig. <ref type="figure" target="#fig_1">2B</ref>). It is hypothesized that TIM3 needs to bind with these specific ligands to exert its immunosuppressive role <ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref>. Among these ligands, Gal-9 was the first to be identified. It functions as a carbohydrate-binding protein with specific recognition of the N-linked glycosylation within the IgV domain of TIM3 <ref type="bibr" target="#b59">[60]</ref> (Fig. <ref type="figure" target="#fig_1">2B</ref>). Studies have demonstrated that stimulation of TIM3 by human Gal-9 leads to an increase in the phosphorylation of Y265 <ref type="bibr" target="#b60">[61]</ref>. In mice, TIM3 exerts its immunosuppressive functions through the phosphorylation of Y256 and Y263 <ref type="bibr" target="#b61">[62,</ref><ref type="bibr" target="#b62">63]</ref>. These phosphorylated residues in the C-terminal of TIM3 bind to SH2-containing STAT1, subsequently inhibiting STAT1 phosphorylation and its translocation into the nucleus. This leads to the downregulation of miR-155, a reduced inhibition of SOCS1 expression, an increase in the expression of IL-10 and Arg-1, ultimately resulting in the polarization of macrophages into M2 phenotypes <ref type="bibr" target="#b61">[62]</ref>. Furthermore, the phosphorylation of Y256 and Y263 in Tim3 also serves to inhibit the activation of the inflammasome NLRP3 <ref type="bibr" target="#b62">[63]</ref>. Bat3 binds to residues 252-270 of TIM3, suppressing Tim-dependent T cell exhaustion. Gal-9 can disrupt this interaction by inducing the phosphorylation of the two tyrosine residues (Y256 and Y263) at the C-terminus of TIM3 <ref type="bibr" target="#b28">[29]</ref> (Fig. <ref type="figure" target="#fig_1">2B</ref>). The binding sites for PtdSer, CEACAM1, and HMGB1 rely on hydrophobic residues located within the FGCC ring <ref type="bibr" target="#b58">[59,</ref><ref type="bibr" target="#b63">64]</ref> (Fig. <ref type="figure" target="#fig_1">2B</ref>). The transport of PtdSer in mitochondria-associated membranes (MAMs) is under the regulation of MET30, a substrate recognition subgroup of the SCF ubiquitination ligase <ref type="bibr" target="#b64">[65,</ref><ref type="bibr" target="#b65">66]</ref>. When TIM3 is not bound to these ligands, the transmembrane domain of TIM3 positively regulates its localization efficiency to immune synapses. Moreover, its cytoplasmic tail contains intrinsic costimulatory activity, effectively activating T cells <ref type="bibr" target="#b27">[28]</ref>. Paradoxically, the expression of TIM3 may lead to T cell exhaustion through continuous TCR signaling after the short-term activation of T cells <ref type="bibr" target="#b28">[29,</ref><ref type="bibr" target="#b29">30]</ref>.</p><p>TIM3 undergoes extracellular domain shedding mediated by ADAM10 and ADAM17. This process results in the generation of a soluble form of TIM3. Interestingly, this shedding is induced by PMA and can be prevented when the amino acids Glu181 to Asp190 within the stem region are absent <ref type="bibr" target="#b66">[67]</ref> (Fig. <ref type="figure" target="#fig_1">2B</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Post-translational modification of LAG3 and its ligand MHC-II</head><p>LAG3, also known as CD233, is a Type I transmembrane protein belonging to the immunoglobulin (Ig) superfamily. It is primarily expressed in activated T cells, NK cells, B cells, and plasma-like DCs <ref type="bibr" target="#b67">[68]</ref>. The structure of LAG3 encompasses three main components: the extracellular, transmembrane, and cytoplasmic regions. Within the extracellular domain, there are distinct segments including a signal peptide, a IgV domain, three IgC2 domains, and a splicing peptide <ref type="bibr" target="#b68">[69]</ref>.</p><p>Notably, the IgV domain and the IgC2-type 1 domain serve as binding sites for LAG3 ligands such as major histocompatibility complex-II (MHC-II) and fibrinogen-like protein 1 (FGL1) <ref type="bibr" target="#b30">[31]</ref>. Additionally, the binding peptides in this domain act as sites for the metalloproteinases ADAM10 and ADAM17 <ref type="bibr" target="#b69">[70,</ref><ref type="bibr" target="#b70">71]</ref>. The cytoplasmic domain of LAG3 comprises three elements: the potential serine phosphorylation site S484, the "KIEELE" motif, and the glutamate-proline dipeptide repeating motif (EP sequence) <ref type="bibr" target="#b71">[72]</ref>. Studies have demonstrated that the key components of the KIEELE motif play a crucial role in LAG3 immune suppression <ref type="bibr" target="#b72">[73]</ref>. However, another study suggested that both S484 and EP sequences are vital components for LAG3 to function. Moreover, S484 may potentially serve as a substrate for protein kinase C (PKC) <ref type="bibr" target="#b71">[72]</ref>. LAG3 exhibits a range of ligands including MHC-II, Galectin-3, LSECtin, and FGL1. Nevertheless, the identity of its ligand remains a subject of debate and necessitates further elucidation. Among these, MHC-II is the primary ligand for LAG3. Galectin-3 is a soluble lectin known for its affinity to galactosides, while LSECtin belongs to the superfamily of C-type lectin receptors. FGL1, discovered by Professor Lieping Chen's team, is an LAG3 ligand independent of MHC-II function. The interaction between FGL1 and LAG3 promotes tumor immune evasion <ref type="bibr" target="#b30">[31]</ref> (Fig. <ref type="figure" target="#fig_2">3A</ref>).</p><p>The LAG3 protein undergoes cleavage by ADAM10 and ADAM17 enzymes, resulting in the breakage of the splicing peptide and the release of soluble LAG3 (sLAG3). This sLAG3 can then bind to MHC-II, activating anti-tumor effects in T cells <ref type="bibr" target="#b70">[71]</ref>.</p><p>MHC-II, the main ligand of LAG3, is regulated by ubiquitination modification. Proteins from the MARCH family, particularly MARCH1 and MARCH8, play a role in downregulating the cell surface expression of MHC-II in dendritic cells (DC), B cells, and monocytes. They achieve this by ubiquitinating the K225 residues in the cytoplasmic region of MHC-II <ref type="bibr" target="#b73">[74]</ref>. Additionally, CD83 acts in opposition to the E3 ligase MARCH8, thereby stabilizing MHC-II <ref type="bibr" target="#b74">[75]</ref>. Furthermore, Salmonella effector (SteD) facilitates the interaction between the TMEM127/WWP2 complex and MHC-II. This interaction leads to the ubiquitination and subsequent degradation of MHC-II on the surface of DCs <ref type="bibr" target="#b75">[76]</ref> (Fig. <ref type="figure" target="#fig_2">3B</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">Post-translational modification of TIGIT/DNAM-1 and its ligands CD155 and CD112</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.1.">Structure of TIGIT/DNAM-1 and its ligands CD155 and CD112</head><p>The immunosuppressive receptor TIGIT is a transmembrane glycoprotein with a structure comprising a signal peptide, an IgV domain, a transmembrane domain, and a cytoplasmic tail that houses an immunoreceptor tyrosine inhibitory motif (ITIM) and an immunoglobulin tyrosine tail-like motif <ref type="bibr" target="#b76">[77]</ref> (Fig. <ref type="figure" target="#fig_3">4A</ref>). TIGIT interacts with multiple ligands, including CD155 (Necl-5), CD112 (Nectin-2), CD113 (Nectin-3), and PVRL4 (Nectin-4) <ref type="bibr" target="#b77">[78]</ref>. Nectin and Necl proteins, which are cell-surface glycoproteins belonging to the immunoglobulin superfamily, play crucial roles in these interactions. The Nectin family encompasses four members (Nectin-1 to Nectin-4), while the Necl family comprises five members (Necl-1 to Necl-5). These proteins feature three Ig extracellular domains that form homodimeric or heterodimeric complexes within the membrane. CD155, for instance, consists of a signal peptide, an IgV domain, two IgC2 domains, a transmembrane domain, and a cytoplasmic domain with an ITIM (Fig. <ref type="figure" target="#fig_3">4C</ref>). CD112, on the other hand, contains a signal peptide, an IgV domain, two IgC2 domains, a transmembrane domain, and a cytoplasmic domain <ref type="bibr" target="#b77">[78,</ref><ref type="bibr" target="#b78">79]</ref> (Fig. <ref type="figure" target="#fig_3">4D</ref>).</p><p>The corresponding activating receptor, DNAM-1, is expressed in both T cells and NK cells. It is a transmembrane glycoprotein composed of a signal peptide, an IgC2-type 1 domain, an IgC2-type 2 domain, a Type I transmembrane domain, and an intracellular domain <ref type="bibr" target="#b79">[80]</ref>. Within the intracellular domain of DNAM-1, there are two highly conserved phosphorylation sites, Y322 and S329 in humans, and Y319 and S326 in mice <ref type="bibr" target="#b80">[81]</ref><ref type="bibr" target="#b81">[82]</ref><ref type="bibr" target="#b82">[83]</ref> (Fig. <ref type="figure" target="#fig_3">4B</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.2.">Post-translational modification of TIGIT</head><p>The cytoplasmic tail of TIGIT serves as the initiator for a cascade of inhibitory signals. In human TIGIT, the ITT-like motif (Y225 and Y231) has been identified as a key player in mediating significant inhibition of signaling <ref type="bibr" target="#b83">[84]</ref>. Following the binding of TIGIT to its ligand, the cytoplasmic tail is phosphorylated and then associates with the solute adaptor GRB2. This interaction facilitates the recruitment of SHIP-1, which contains the Src homology 2 (SH2) domain. Subsequently, SHIP-1 works to suppress the signaling cascade of PI3K and MAPK <ref type="bibr" target="#b83">[84]</ref> (Fig. <ref type="figure" target="#fig_3">4E</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.3.">Post-translational modification of DNAM-1</head><p>Phosphorylation of DNAM-1 at Y322 is crucial for TIGIT blockade <ref type="bibr" target="#b82">[83]</ref>. When both TIGIT and DNAM-1 are present, CD155 shows a preference for binding to TIGIT <ref type="bibr" target="#b84">[85]</ref>. This interaction leads to the phosphorylation of the cytoplasmic tail of TIGIT, resulting in the inhibition of T cell response. However, TIGIT blockade disrupts CD155-induced TIGIT phosphorylation, subsequently restoring the phosphorylation of DNAM-1 at Y322 and ultimately promoting T cell activation <ref type="bibr" target="#b82">[83]</ref>. PKC phosphorylates specific serine residues (S329) of DNAM-1, facilitating the association of LFA-1 with DNAM-1 <ref type="bibr" target="#b85">[86]</ref>. This interaction leads to the binding of LFA-1 to ICAM-1, inducing a conformational change and subsequent recruitment of Fyn. This in turn triggers the phosphorylation of Y322 residues of DNAM-1, ultimately activating effector T cells <ref type="bibr" target="#b86">[87]</ref>. In the presence of LFA-1, DNAM-1 is dephosphorylated by PD-1-SHP2, but treatment with PD-1 antibodies leads to a high level of phosphorylation <ref type="bibr" target="#b87">[88]</ref> (Fig. <ref type="figure" target="#fig_3">4E</ref>).</p><p>The expression of DNAM-1 is post-translationally regulated through the ubiquitin-proteasome pathway. In conjunction with CD155, mouse DNAM-1 undergoes phosphorylation at Y319 by the kinase Scr. This phosphorylation event subsequently recruits the E3 ubiquitin ligase Cblb, leading to the ubiquitination of phosphorylated DNAM-1 and its subsequent proteasome-dependent degradation <ref type="bibr" target="#b88">[89]</ref> (Fig. <ref type="figure" target="#fig_3">4E</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.4.">Post-translational modification of CD155 and CD112</head><p>Phosphorylation of CD155 affects its function. When DNAM-1 binds to human CD155, Y398 within the ITIM of CD155 undergoes phosphorylation, subsequently recruiting SHP-2. This event is accompanied by the dephosphorylation of plaque kinases and pilin, leading to the  inhibition of cell adhesion and an increase in cellular mobility <ref type="bibr" target="#b89">[90]</ref>. In cases of hepatocellular carcinoma (HCC), the activation of the UPR inhibits the surface expression of CD155 and promotes its degradation <ref type="bibr" target="#b90">[91]</ref>.</p><p>Moreover, ubiquitination and SUMOylation play negative regulatory roles in the surface expression of CD112 and CD155 in tumor cells.</p><p>While ubiquitinated CD112 is retained within the intracellular compartment, it is also targeted for proteasomal degradation. The US2 gene product of the human cytomegalovirus (HCMV) mediates the polyubiquitination and subsequent degradation of CD112 via TRC8, with the assistance of the maintenance enzyme UL141 <ref type="bibr" target="#b91">[92]</ref>. CD155 can be modulated through SUMO modification, and inhibiting SUMOylation facilitates the transfer of CD155 from the cytoplasm to the cell membrane <ref type="bibr" target="#b92">[93]</ref>. Inhibiting the Ubiquitin and SUMO pathways results in increased expression of CD112 and CD155 on the cell surface, rendering tumor cells more susceptible to NK-cell-mediated killing <ref type="bibr" target="#b93">[94]</ref> (Fig. <ref type="figure" target="#fig_3">4E</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.">Post-translational modification of KIR and MHC-I</head><p>Killer cell immunoglobulin-like receptors (KIRs) constitute a group of polymorphic transmembrane glycoproteins primarily expressed on NK cells. KIRs play a critical role in regulating NK cell function, functioning as both activators and inhibitors. They possess a long intracellular domain and a short intracellular domain <ref type="bibr" target="#b94">[95]</ref>.</p><p>Among the confirmed KIR ligands, MHC-I stands out. There's a consistent pattern of ubiquitination observed in MHC-II and CD86. Homologous products such as miR1, miR2, murine γ-herpesvirus-K3 (mK3) , M153R of myxoma virus, MARCH4, and MARCH9 have been reported to reduce MHC-I expression. They achieve this by binding to lysine (K63) in the cytoplasmic tail of the MHC-I protein, consequently triggering endocytosis and lysosomal degradation <ref type="bibr" target="#b95">[96]</ref>. Interestingly, some viruses can mediate MHC-I ubiquitination even in the absence of a lysine residue in the cytoplasmic tail. For instance, the US2 gene product of the HCMV is known to mediate MHC-I polyubiquitination hydrolysis through TRC8. Additionally, the US11 gene product facilitates the hydrolysis of MHC-I polyubiquitination by interacting with Derlin-1, which in turn binds to TMEM129, an uncharacterized RING-C2 E3 ligase <ref type="bibr" target="#b96">[97]</ref> (Fig. <ref type="figure" target="#fig_3">4E</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.">Post-translational modification of NKG2D and its ligands MICA/B and ULBP2</head><p>NKG2D is a type II transmembrane receptor protein (42 KDa) encoded by the KLRK1 gene. It comprises an intracellular domain, a transmembrane domain, and an extracellular domain containing a type C lectin domain <ref type="bibr" target="#b97">[98]</ref>. The ligands for NKG2D include human major histocompatibility complex class I-related chain A and B) (MICA and MICB) and human ULBP1-6. Most of these are multi-segment transmembrane proteins, but some, such as ULBP1/2/3/6, lack a transmembrane structure and are anchored to the cell membrane by glycophosphatidylinositol. These can be preferentially released via an exosome form <ref type="bibr" target="#b98">[99]</ref> (Fig. <ref type="figure" target="#fig_4">5A-D</ref>).</p><p>MICA, MICB, and ULBP2 can be cleaved by matrix metalloproteinases (MMPs) and ADAMs to form soluble proteins. In glioblastoma, ADAM10 and ADAM17 contribute to an immunosuppressive phenotype by hydrolyzing and cleaving ULBP2 <ref type="bibr" target="#b99">[100]</ref>. Additionally, MICA binds to endoplasmic reticulin 5 (ERp5; also known as PDIA6 or P5) on the surface of tumor cells, where ERp5 is necessary for MICA shedding. ERp5 and membrane-anchored MICA form a transient hybrid disulfide complex, leading to the release of soluble MICA through proteolytic cleavage near the cell membrane <ref type="bibr" target="#b100">[101]</ref> (Fig. <ref type="figure" target="#fig_4">5E</ref>).</p><p>Fatty acylation and palmitoylation of MICA/B impact protein recruitment in the membrane microdomain, thereby affecting proteolytic cleavage. The 306th and 307th cysteine residues in the cytoplasmic tail of MICA, which are 330th and 331th in the total length of the peptide chain, are crucial for MICA palmitoylation and recruitment to DRM/caveolae, promoting the release of soluble MICA molecules <ref type="bibr" target="#b101">[102]</ref> (Fig. <ref type="figure" target="#fig_4">5C</ref>).</p><p>MICA also possesses multiple N-linked glycosylation sites. It has been reported that hypoxia inhibits N-glycosylation of MICA protein, consequently suppressing its expression on the cell surface <ref type="bibr" target="#b102">[103]</ref>. While N-glycosylation is not essential for interaction with MICA/NKG2D, it enhances complex formation <ref type="bibr" target="#b103">[104]</ref> (Fig. <ref type="figure" target="#fig_4">5E</ref>).</p><p>Long-term exposure to soluble or membrane-bound NKG2DLs leads to the downregulation of receptor expression. Studies have indicated that c-Cbl serves as a ubiquitin ligase to degrade NKG2D when bound with NKG2D, triggered by c-Cbl tyrosine phosphorylation <ref type="bibr" target="#b104">[105]</ref>. The immature form of MICA accumulates in the endoplasmic reticulum and undergoes degradation via the ubiquitin pathway and lysosomal processes. Histamine reduces MICA by activating H1R and H2R-mediated ubiquitin-proteasome pathways, ultimately reducing sensitivity to NK cells <ref type="bibr" target="#b105">[106]</ref> (Fig. <ref type="figure" target="#fig_4">5E</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.">Post-translational modification of CD47 and its ligand SIRPα</head><p>CD47 is a transmembrane protein commonly found on the surface of normal cells. Its molecular structure comprises an extracellular variable domain at the N-end, five hydrophobic transmembrane helix structures, and a very short intracellular signaling sequence at the C-terminal <ref type="bibr" target="#b106">[107]</ref>. By binding to SIRPα, CD47 inhibits the phagocytosis of macrophages. This interaction is often overexpressed on the surface of tumor cells, acting as an "accomplice" in immune evasion. SIRPα, also known as SHPS-1, is a transmembrane protein with an IgV domain at the NH2 end and two IgC domains that interact with CD47 <ref type="bibr" target="#b106">[107]</ref> (Fig. <ref type="figure" target="#fig_5">6A</ref>).</p><p>The combination of CD47 with SIRPα induces the phosphorylation of tyrosine in SIRPα ITIM. Phosphorylated ITIM then recruits and activates the tyrosine phosphatase SHP-2 protein. The activated tyrosine phosphatase further dephosphorylates a series of proteins in the cell, ultimately inhibiting macrophage phagocytosis <ref type="bibr" target="#b107">[108]</ref>. EGFR activation leads to increased CD47 expression by enhancing c-Src binding to CD47. This, in turn, triggers c-Src-mediated phosphorylation of CD47 at Y288. This phosphorylation disrupts the interaction between the ubiquitin E3 ligase TRIM21 and CD47, preventing TRIM21-mediated K99/102 multi-ubiquitination and degradation of CD47 <ref type="bibr" target="#b108">[109]</ref> (Fig. <ref type="figure" target="#fig_5">6B</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.">Post-translational modification of B7-H4</head><p>B7-H4, encoded by the VTCN1 gene, is a GPI-conjugated protein that comprises a signal peptide, two IgV-like domains, a transmembrane region, and a cytoplasmic region <ref type="bibr" target="#b109">[110]</ref> (Fig. <ref type="figure" target="#fig_5">6C</ref>). This protein is expressed in activated T and B cells, monocytes, and dendritic cells. It's notably overexpressed in multiple tumors but absent in most normal tissues <ref type="bibr" target="#b110">[111]</ref>. In triple-negative breast cancer (TNBC), the stability of B7-H4 is governed by AMFR-mediated ubiquitination and STT3A-dependent glycosylation <ref type="bibr" target="#b111">[112]</ref>. UGGG1, an ER-associated enzyme, selectively glycosylates unfolded proteins, thereby promoting the glycosylation of B7-H4 <ref type="bibr" target="#b111">[112,</ref><ref type="bibr" target="#b112">113]</ref> (Fig. <ref type="figure" target="#fig_5">6D</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="10.">Post-translational modification of B7-H6</head><p>B7-H6, encoded by the NCR3LG1 gene, is a type I transmembrane protein consisting of a signal peptide, an IgV-like domain with multiple glycosylation sites, an IgC1-like domain, and transmembrane and intracellular regions <ref type="bibr" target="#b109">[110]</ref> (Fig. <ref type="figure" target="#fig_5">6E</ref>). This protein exhibits specific expression in various tumor tissues and acts as a membrane-binding ligand for the surface-activating receptor NKp30 in NK cells. B7-H6 can be shed from the cell surface in the form of exosomes, generating soluble B7-H6 on the cell surface, which subsequently downregulates NKp30-mediated NK cytotoxicity and cytokine secretion. This extracellular shedding of B7-H6 relies on cleavage through the hydrolytic action of ADAM10 and ADAM17 <ref type="bibr" target="#b113">[114]</ref> (Fig. <ref type="figure" target="#fig_5">6F</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="11.">Clinical translation and future perspectives of posttranslational modification of immune checkpoint</head><p>Cancer immunotherapy, particularly targeting immune checkpoint molecules, has emerged as a pivotal area of research in recent years. Despite its promise, it faces various limitations, such as the limited efficacy observed when using TIM3 and LAG3 blocking antibodies alone. Additionally, the use of CD47 antibodies or SIRPα-Fc may result in erythrocyte toxicity <ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b21">22]</ref>. To address these challenges, this summary explores the post-translational modifications of immune checkpoints, clarifies the molecular mechanisms governing these modifications, and suggests novel targets that could function as both biomarkers and potential therapeutic avenues for unleashing immune system blockades. In addition, these novel immune checkpoint therapies, in combination with other drugs, may be critical to improving outcomes for more patients.</p><p>One critical aspect influencing the efficacy of immunotherapy is glycosylation modification. Notably, NGI-1, an OST small molecule inhibitor, demonstrates significant potential <ref type="bibr" target="#b111">[112]</ref>. It functions by inhibiting the activities of STT3A and STT3B, subsequently impeding the glycosylation of B7-H4 of TNBC. This, in turn, leads to ubiquitination and subsequent degradation of the protein. In parallel, glucose analogs like 2-deoxyglucose (2-DG) have emerged as competitive inhibitors of hexose kinases, effectively suppressing glycolysis. Furthermore, they interfere with the synthesis of N-glycosylation in proteins. Notably, 2-DG exerts its influence by inhibiting the N-glycosylation of MICA, thus preventing its expression on the surface of osteosarcoma cells <ref type="bibr" target="#b102">[103]</ref>. The impact of glycosylation isn't confined to protein targets alone. Therapeutic antibodies, vital in immune checkpoint blockade strategies, are also subject to glycosylation modification. For instance, SEA-TGT, a monoclonal antibody designed to counteract TIGIT non-ligand glycosylation, leverages proprietary glycoengineered antibody (SEA) technology (Fig. <ref type="figure" target="#fig_6">7</ref>). This augmentation significantly enhances its Fc-γ RIIIa affinity and antibody-dependent cellular cytotoxicity (ADCC) activity. The combined administration of SEA-TGT and anti-PD-1 antibodies holds tremendous promise in depleting TIGIT-overexpressing T cells, thereby reinstating T cell populations and bolstering anti-tumor immune responses in the mouse models of colorectal cancer and renal cell carcinoma <ref type="bibr" target="#b114">[115]</ref>. Presently, SEA-TGT is undergoing Phase 1/2 clinical trials for the treatment of advanced solid tumors and lymphomas, marked by identifiers NCT04254107 and NCT04585815 (Fig. <ref type="figure" target="#fig_6">7</ref>, Table <ref type="table" target="#tab_0">1</ref>).</p><p>The administration of the MMP broad-spectrum inhibitor Batimastat has demonstrated a notable augmentation in NK cell activity. This effect is attributed to the reduction in serum levels of sULBP2, concomitant with an increase in ULBP2 expression within cancer cells <ref type="bibr" target="#b115">[116]</ref>. Furthermore, inhibitors with specificities towards ADAM, such as GW280264X, the MMP inhibitor Periostat, and the FAAH inhibitor URB597, exhibit potential in mitigating sMICA/B-induced tumor immune evasion in breast cancer and liver cancer models <ref type="bibr" target="#b116">[117]</ref><ref type="bibr" target="#b117">[118]</ref><ref type="bibr" target="#b118">[119]</ref>. Presently, only Periostat has progressed to clinical trial stages of melanoma and non-Hodgkin's lymphoma (NHL) (NCT01590082 and NCT02086591). Despite some setbacks faced by MMP and ADAM inhibitors in clinical trials, their candidacy as therapeutic targets remains compelling, as supported by encouraging preclinical outcomes. Of particular significance is the recent development of functionally blocking antibodies against ADAM17. In a co-culture model of NK cells and ovarian cancer cells, the anti-ADAM17 monoclonal antibody MEDI3622 effectively inhibited ADAM17 in NK cells, leading to increased IFN-γ secretion <ref type="bibr" target="#b119">[120]</ref>. (Fig. <ref type="figure" target="#fig_6">7</ref>, Table <ref type="table" target="#tab_0">1</ref>).</p><p>Several monoclonal antibodies targeting MICA have exhibited promising preclinical efficacy. The use of the sMICA neutralizing and non-blocking monoclonal antibody (B10G5) enhances the sensitivity of MIC-expressing tumor cells to NK cell killing in mouse prostate cancer models with specific human MIC expression. This leads to effective regression of primary tumors and elimination of metastasis without inducing systemic toxicity <ref type="bibr" target="#b120">[121]</ref>. Similar positive outcomes were observed in the NSG mouse model of human pancreatic cancer cells <ref type="bibr" target="#b121">[122]</ref>. Notably, the combination of B10G5 with PD-L1 blockade significantly enhances the synergistic therapeutic effects of NK cells and CD8 + T cells on melanoma <ref type="bibr" target="#b120">[121]</ref>. Another MICA/B-specific monoclonal antibody, denoted as 7C6, has shown inhibitory effects on the growth of various malignancies, including melanoma, colon, and intrahepatic cholangiocarcinoma. This effect is attributed to the antibody's ability to counteract the loss of MICA and MICB <ref type="bibr" target="#b122">[123]</ref>. Furthermore, 7C6 has displayed synergistic effects with histone deacetylase inhibitors (HDACi), particularly in stabilizing MICA/B expression on the surface of acute myeloid leukemia (AML) cells <ref type="bibr" target="#b123">[124]</ref>. Additionally, the chimeric protein BLS-MICA, characterized by its extracellular domain binding to Brucella spp lumazine synthase (BLS), has exhibited significant potential <ref type="bibr" target="#b124">[125]</ref>. In vivo studies with BLS-MICA have shown the generation of high titers of anti-MICA antibodies in murine lymphoma cells and bladder cancer models stably expressing human MICA. This immune response resulted in the elimination of tumors through ADCC. MICA exhibits high expression in various cancers, including breast, colorectal, liver, lung adenocarcinoma, lung squamous cell carcinoma, stomach, kidney, ovarian, melanoma, leukemia, and multiple myeloma (MM) <ref type="bibr" target="#b125">[126]</ref><ref type="bibr" target="#b126">[127]</ref><ref type="bibr" target="#b127">[128]</ref>. This novel anti-tumor vaccine shows promise for patients with MICA-positive cancers <ref type="bibr" target="#b124">[125]</ref>.</p><p>The soluble LAG3-Ig fusion protein IMP321 (Eftilagimod Alpha) has been demonstrated to enhance T-lymphocyte-mediated antitumor immunity in targeted mouse models <ref type="bibr" target="#b128">[129]</ref>. IMP321 is currently undergoing clinical trials as an immune-enhancing agent in breast cancer, melanoma, NSCLC, head and neck squamous cell carcinoma (HNSCC) (ClinicalTrials.gov identifiers: NCT03252938, NCT00349934, NCT00351949, NCT02676869, NCT01308294, NCT02614833), with ongoing investigations into its combination with antiviral vaccines, chemotherapy, and other anti-tumor therapies <ref type="bibr" target="#b129">[130]</ref><ref type="bibr" target="#b130">[131]</ref><ref type="bibr" target="#b131">[132]</ref> (Fig. <ref type="figure" target="#fig_6">7</ref>, Table <ref type="table" target="#tab_0">1</ref>).</p><p>Proteasome inhibitors wield significant influence over the destiny of ubiquitinated ligands. Bortezomib, an FDA-approved reversible inhibitor of the 26S proteasome, has shown the ability, even at low doses, to upregulate the expression of NK cell activation ligands on multiple myeloma cells, including CD155, CD112, and ULBPs. However, the precise mechanism underlying this effect remains to be elucidated <ref type="bibr" target="#b132">[133]</ref>. Furthermore, bortezomib has been found to upregulate the expression of MICA/B by inhibiting proteasome activity <ref type="bibr" target="#b132">[133]</ref>.</p><p>While the CD47/SIRPα pathway is a promising candidate for current cancer immunotherapy, systemic blockade of CD47 (also expressed on red blood cells) can lead to severe anemia. Proteolysis-targeting chimeras (PROTACs) technology is a novel drug strategy to degrade targeted proteins utilizing the ubiquitin-proteasome system (UPS). It has been proved to achieve cell/tissue selectivity and alleviate the toxicity of traditional small molecule inhibitors <ref type="bibr" target="#b133">[134]</ref>. Existing studies indicate that the use of nano-protein-hydrolyzing targeted chimeras (nano--PROTACs) induces targeted degradation of SHP-2, thereby disrupting the CD47/SIRPα pathway <ref type="bibr" target="#b134">[135]</ref>. Furthermore, E3 ligase-dependent ubiquitination has been well validated in the regulation of CD47  degradation <ref type="bibr" target="#b108">[109]</ref>. Therefore, we hypothesize that inhibition of the CD47/SIRPα axis by PROTAC holds broad potential for future drug development.</p><p>Pevonedistat (MLN4924, TAK-924) stands out as a first-in-class NAE inhibitor with a low molecular weight. In the context of multiple myeloma, which is characterized by diminished anti-cancer/cytotoxic activity of NK cells, Pevonedistat demonstrates the capacity to inhibit neddylation of MICB in various multiple myeloma cell lines. This action induces the accumulation of MICB on the cell membrane <ref type="bibr" target="#b135">[136]</ref>. Currently, Pevonedistat is under clinical investigation for various malignancies, including AML, myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), acute lymphoblastic leukemia (ALL), MM, lymphoma, and other hematologic malignancies (ClinicalT rials.gov identifiers: NCT01814826, NCT00911066, NCT03323034, NCT03745352, NCT03770260, NCT03862157, NCT03479268, and NCT03268954) <ref type="bibr" target="#b136">[137,</ref><ref type="bibr" target="#b137">138]</ref>. It is also part of phase I/II clinical trials for solid tumors such as NSCLC, breast cancer, HNSCC, ovarian cancer, intrahepatic cholangiocarcinoma (ICC), colorectal cancer (CRC), melanoma, gastric cancer, etc (ClinicalTrials.gov identifiers: NCT01862328, NCT03323034, NCT03965689, NCT03057366, NCT04175912, and jRCT2031190020) <ref type="bibr" target="#b138">[139,</ref><ref type="bibr" target="#b139">140]</ref>. Notably, Pevonedistat is primarily employed in combination with other drugs. However, results from Phase III clinical trials for the treatment of MDS, CMML, and AML with a combination of Pevonedistat and AZA did not reveal a significant improvement in overall clinical outcomes compared to AZA alone. This suggests that the addition of any extra agents may impact the effectiveness of Pevonedistat. The potential use of Pevonedistat in combination with other promising therapies and its future directions remain subjects for exploration <ref type="bibr" target="#b140">[141]</ref> (Fig. <ref type="figure" target="#fig_6">7</ref>, Table <ref type="table" target="#tab_0">1</ref>).</p><p>Ginkgolic Acid (GA), an inhibitor targeting the SUMO-activating E1 enzyme SAE1/UBA2, emerges as a potent modulator. When applied to multiple myeloma cell lines or CD138 + plasma cells from patients, GA demonstrates the ability to enhance CD155 expression on MM cells <ref type="bibr" target="#b92">[93]</ref>. This heightened activation is particularly pronounced in co-culture systems with autologous NK cells from patients, significantly promoting NK cell lysis of MM cells. Flow cytometry analysis of plasma cells from patients treated with GA further substantiates this finding by revealing an upregulation of CD155 expression <ref type="bibr" target="#b92">[93]</ref>. Moreover, preclinical studies shed light on the potential of the selective small molecule SUMOylation inhibitor TAK-981 (Subasumstat). In mouse models of pancreatic ductal adenocarcinoma (PDAC), HCC, CD20 + lymphoma, and colorectal cancer, TAK-981 induces the activation of NK cells and CD8 + T cells, thereby enhancing the anti-tumor immune response <ref type="bibr" target="#b141">[142]</ref><ref type="bibr" target="#b142">[143]</ref><ref type="bibr" target="#b143">[144]</ref><ref type="bibr" target="#b144">[145]</ref>. Currently, TAK-981 is being assessed in clinical trials involving patients with various solid tumors (ClinicalTrials.gov identifiers: NCT04074330, NCT04776018, NCT04381650, NCT04065555, and NCT03648372) (Fig. <ref type="figure" target="#fig_6">7</ref>, Table <ref type="table" target="#tab_0">1</ref>).</p><p>With our deepening understanding of the etiology of diseases, it is increasingly apparent that post-translational modifications of proteins represent a pivotal class of targets with potential applications in diverse disease areas. Whether in the context of hematologic cancers or solid tumors, we anticipate that the development of innovative techniques for deciphering post-translational protein modifications will open up new avenues for advancing tumor immunotherapies, ultimately offering renewed hope for patients.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="12.">Availability of data and materials</head><p>Not applicable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="13.">Ethics approval and consent to participate</head><p>Not applicable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="14.">Consent for publication</head><p>All authors have agreed to publish this manuscript. </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 .</head><label>1</label><figDesc>Fig. 1. Diagram of post-translational modification of novel immune checkpoints. A. N-linked glycosylation modification. B. Phosphorylation modification. C. Ubiquitination modification. D. Neddylation modification. E. SUMOylation modification. F. Palmitoylation modification. G. Ectodomain shedding.</figDesc><graphic coords="3,70.24,55.42,454.75,595.58" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 .</head><label>2</label><figDesc>Fig. 2. Schematic illustration of TIM3's structure and its molecular mechanism diagram of post-translational modification. A. Structure and post-translational modifier sites of TIM3 protein. B. Regulatory mechanisms of post-translational modification of TIM3 and its ligands.</figDesc><graphic coords="4,126.99,318.93,341.28,397.73" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 3 .</head><label>3</label><figDesc>Fig. 3. Schematic illustration of LAG3's structure and its molecular mechanism diagram of post-translational modification. A. Structure and post-translational modifier sites of LAG3 protein. B. Regulatory mechanisms of post-translational modification of LAG3 and its ligands.</figDesc><graphic coords="6,126.99,55.43,341.28,422.21" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig. 4 .</head><label>4</label><figDesc>Fig. 4. The structure and post-translational modifications of TIGIT/DNAM-1 and their ligands, CD155 and CD112. A. Structure and sites of post-translational modifications on the TIGIT protein. B. Structure and sites of post-translational modifications on DNAM-1. C. Structure and sites of post-translational modifications on CD155. D. Structure and sites of post-translational modifications on CD112. E. Molecular mechanism diagram of post-translational modifications in TIGIT/ DNAM-1 and their ligands, CD155 and CD112.</figDesc><graphic coords="7,84.36,55.43,426.53,598.75" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Fig. 5 .</head><label>5</label><figDesc>Fig. 5. Structure and post-translational modification NKG2D and its ligands MICA/B and ULBP2, along with the regulation of post-translational modifications in KIR/MHC-I. A. Structure and post-translational modification sites of NKG2D protein. B. Structure and post-translational modification sites of ULBP2. C. Structure and post-translational modification sites of MICA. D. Structure and post-translational modification sites of MICB. E. Molecular mechanism diagram of post-translational modifications in NKG2D, MICA/B, ULBP2, KIR and MHC-I</figDesc><graphic coords="8,84.36,130.77,426.53,566.78" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Fig. 6 .</head><label>6</label><figDesc>Fig. 6. Structure and post-translational modification of CD47/SIRPα, B7-H4 and B7-H6. A. Structure and post-translational modification sites of SIRPα. B. Posttranslational modification of CD47/SIRPα. C. Structure and post-translational modification sites of B7-H4. D. Post-translational modification of B7-H4. E. Structure and post-translational modification sites of B7-H6. F. Post-translational modification of B7-H6.</figDesc><graphic coords="10,113.10,55.44,369.07,328.32" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Fig. 7 .</head><label>7</label><figDesc>Fig. 7. An overview of suitable therapies for the post-translational modification of various immune checkpoints. The green, blue, red, yellow, and orange regions of the innermost ring of the circle represent glycosylation, ectodomain shedding, ubiquitination, neddylation and SUMOylation in turn. The corresponding intermediate ring in turn represents various immune checkpoint related molecules regulated by post-translational modifications. The outermost ring corresponds to treatments that target these molecules. The green, blue, red, yellow, and orange regions of the innermost ring of the circle represent glycosylation, ectodomain shedding, ubiquitination, neddylation, and SUMOylation, respectively. The corresponding intermediate ring represents various immune checkpoint-related molecules regulated by post-translational modifications. The outermost ring corresponds to treatments that target these molecules.</figDesc><graphic coords="11,126.99,55.41,341.28,340.42" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc>Clinical trials of targeted PTMs therapy.</figDesc><table><row><cell>Drug</cell><cell>Target</cell><cell>PTM</cell><cell>Disease</cell><cell>Response Rate</cell><cell>Clinical trial No. &amp;</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Phase</cell></row><row><cell>SEA-TGT,</cell><cell>TIGIT</cell><cell>Glycosylation</cell><cell>Advanced Cancer (NSCLC, gastric/GE junction</cell><cell>/</cell><cell>NCT04254107</cell></row><row><cell>Brentuximab Vedotin</cell><cell>CD30</cell><cell></cell><cell>carcinomas, cutaneous melanoma, HNSCC,</cell><cell></cell><cell>Phase 1</cell></row><row><cell></cell><cell></cell><cell></cell><cell>bladder cancer, ovarian cancer, TNBC, CHL or</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>DLBCL)</cell><cell></cell><cell></cell></row><row><cell>SEA-TGT, Sasanlimab</cell><cell>TIGIT</cell><cell>Glycosylation</cell><cell>Advanced NSCLC</cell><cell>/</cell><cell>NCT04585815</cell></row><row><cell></cell><cell>PD-1</cell><cell></cell><cell></cell><cell></cell><cell>Phase 1,2</cell></row><row><cell>Periostat,</cell><cell>MMP2,</cell><cell>Ectodomain</cell><cell>Melanoma</cell><cell>No CR or PR，SD:30%</cell><cell>NCT01590082</cell></row><row><cell>Temozolomide and</cell><cell>MMP9</cell><cell>shedding of MICA</cell><cell></cell><cell></cell><cell>Phase 1,2</cell></row><row><cell>Lpilimumab</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Periostat, Metformin</cell><cell>MMP2,</cell><cell>Ectodomain</cell><cell>Relapsed NHL</cell><cell>ORR:28%</cell><cell>NCT02086591</cell></row><row><cell></cell><cell>MMP9</cell><cell>shedding of MICA</cell><cell></cell><cell></cell><cell>Phase 2</cell></row><row><cell>IMP321,</cell><cell>MHC-II</cell><cell>Ectodomain</cell><cell>Advanced Solid Tumors</cell><cell>/</cell><cell>NCT03252938</cell></row><row><cell>Avelumab</cell><cell>PD-L1</cell><cell>shedding of LAG3</cell><cell></cell><cell></cell><cell>Phase 1</cell></row><row><cell>IMP321</cell><cell>MHC-II</cell><cell>Ectodomain</cell><cell>Metastatic Breast Carcinoma</cell><cell>ORR:50%</cell><cell>NCT00349934</cell></row><row><cell></cell><cell></cell><cell>shedding of LAG3</cell><cell></cell><cell></cell><cell>Phase 1</cell></row><row><cell>IMP321</cell><cell>MHC-II</cell><cell>Ectodomain</cell><cell>Metastatic RCC</cell><cell>SD:87.5% patients in higher doses</cell><cell>NCT00351949</cell></row><row><cell></cell><cell></cell><cell>shedding of LAG3</cell><cell></cell><cell>IMP321＞6 mg</cell><cell>Phase 1</cell></row><row><cell>IMP321, Pembrolizumab</cell><cell>MHC-II</cell><cell>Ectodomain</cell><cell>Unresectable or Metastatic Melanoma</cell><cell>/</cell><cell>NCT02676869</cell></row><row><cell></cell><cell>PD-1</cell><cell>shedding of LAG3</cell><cell></cell><cell></cell><cell>Phase 1</cell></row><row><cell>IMP321</cell><cell>MHC-II</cell><cell>Ectodomain</cell><cell>HLA-A2(+) Stage II-IV Melanoma</cell><cell>SD:83.3% and PD:16.7% in</cell><cell>NCT01308294</cell></row><row><cell></cell><cell></cell><cell>shedding of LAG3</cell><cell></cell><cell>Disease-Free Patients</cell><cell>Phase 1,2</cell></row><row><cell>IMP321, Paclitaxel and</cell><cell>MHC-II</cell><cell>Ectodomain</cell><cell>Metastatic breast carcinoma</cell><cell>/</cell><cell>NCT02614833</cell></row><row><cell>Placebo</cell><cell></cell><cell>shedding of LAG3</cell><cell></cell><cell></cell><cell>Phase 1</cell></row><row><cell>IMP321, Montanide ISA51</cell><cell>MHC-II</cell><cell>Ectodomain</cell><cell>Disease-Free Melanoma</cell><cell>/</cell><cell>NCT00365937</cell></row><row><cell></cell><cell></cell><cell>shedding of LAG3</cell><cell></cell><cell></cell><cell>Phase 1,2</cell></row><row><cell>IMP321</cell><cell>MHC-II</cell><cell>Ectodomain</cell><cell>Advanced Pancreas Cancer</cell><cell>/</cell><cell>NCT00732082</cell></row><row><cell></cell><cell></cell><cell>shedding of LAG3</cell><cell></cell><cell></cell><cell>Phase 1</cell></row><row><cell>IMP321, Pembrolizumab</cell><cell>MHC-II</cell><cell>Ectodomain</cell><cell>Previously Untreated Unresectable or Metastatic</cell><cell>/</cell><cell>NCT03625323</cell></row><row><cell></cell><cell>PD-1</cell><cell>shedding of LAG3</cell><cell>NSCLC, or Recurrent PD-X Refractory NSCLC or</cell><cell></cell><cell>Phase 2</cell></row><row><cell></cell><cell></cell><cell></cell><cell>Recurrent or Metastatic HNSCC</cell><cell></cell><cell></cell></row><row><cell>IMP321, Paclitaxel</cell><cell>MHC-II</cell><cell>Ectodomain</cell><cell>ER,PR (+)Metastatic Breast Carcinoma</cell><cell>/</cell><cell>NCT04252768</cell></row><row><cell></cell><cell></cell><cell>shedding of LAG3</cell><cell></cell><cell></cell><cell>Phase 1</cell></row><row><cell>IMP321, Pembrolizumab</cell><cell>MHC-II</cell><cell>Ectodomain</cell><cell>Recurrent or Metastatic HNSCC</cell><cell>/</cell><cell>NCT04811027</cell></row><row><cell></cell><cell>PD-1</cell><cell>shedding of LAG3</cell><cell></cell><cell></cell><cell>Phase 2</cell></row><row><cell>IMP321, adoptive</cell><cell>MHC-II</cell><cell>Ectodomain</cell><cell>Metastatic Melanoma</cell><cell>/</cell><cell>NCT00324623</cell></row><row><cell>immunotherapy</cell><cell>PD-1</cell><cell>shedding of LAG3</cell><cell></cell><cell></cell><cell>Phase 1</cell></row><row><cell>IMP321, Paclitaxel and</cell><cell>MHC-II</cell><cell>Ectodomain</cell><cell>Metastatic Breast Cancer</cell><cell>/</cell><cell>NCT05747794</cell></row><row><cell>Placebo</cell><cell></cell><cell>shedding of LAG3</cell><cell></cell><cell></cell><cell>Phase 2,3</cell></row><row><cell>MLN4924 +docetaxel</cell><cell>MICB</cell><cell>Neddylation</cell><cell>Solid Tumors(NSCLC, breast cancer, HNSCC,</cell><cell>ORR:16% (arm 1) and 35% (arm 2)</cell><cell>NCT01862328</cell></row><row><cell>(arm1)，or carboplatin</cell><cell></cell><cell></cell><cell>ovarian cancer, ICC, CRC, melanoma)</cell><cell>[137]</cell><cell>Phase 1</cell></row><row><cell>and paclitaxel</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>(arm2)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>MLN4924,</cell><cell>MICB</cell><cell>Neddylation</cell><cell>Treatment-naive Participants AML who were 60</cell><cell>ORR:83%[140]</cell><cell>NCT01814826</cell></row><row><cell>Azacitidine</cell><cell></cell><cell></cell><cell>years of age or older</cell><cell></cell><cell>Phase 1</cell></row><row><cell>MLN4924,</cell><cell>MICB</cell><cell>Neddylation</cell><cell>AML, MDS, and ALL</cell><cell>ORR:17%(plan A)，</cell><cell>NCT00911066</cell></row><row><cell>Azacitidine</cell><cell></cell><cell></cell><cell></cell><cell>10%(plan B)[139]</cell><cell>Phase 1</cell></row><row><cell>MLN4924,</cell><cell>MICB</cell><cell>Neddylation</cell><cell>Recurrent or Refractory Solid Tumors or</cell><cell>ORR:16.7%</cell><cell>NCT03323034</cell></row><row><cell>Irinotecan, and</cell><cell></cell><cell></cell><cell>Lymphoma</cell><cell></cell><cell>Phase 1</cell></row><row><cell>Temozolomide</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>MLN4924,</cell><cell>MICB</cell><cell>Neddylation</cell><cell>Relapsed or Refractory AML</cell><cell>/</cell><cell>NCT03745352</cell></row><row><cell>Azacitidine</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Phase 2</cell></row><row><cell>MLN4924,</cell><cell>MICB</cell><cell>Neddylation</cell><cell>Relapsed or Does Not Respond to Treatment MM</cell><cell>/</cell><cell>NCT03770260</cell></row><row><cell>Azacitidine</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Phase 1</cell></row><row><cell>MLN4924, carboplatin and</cell><cell>MICB</cell><cell>Neddylation</cell><cell>Advanced NSCLC Treated With Immunotherapy</cell><cell>/</cell><cell>NCT03965689</cell></row><row><cell>paclitaxel</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Phase 2</cell></row><row><cell>MLN4924,</cell><cell>MICB</cell><cell>Neddylation</cell><cell>Newly Diagnosed AML</cell><cell>/</cell><cell>NCT03862157</cell></row><row><cell>Azacitidine and</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Phase 1,2</cell></row><row><cell>Venetoclax</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>[14 C]-Pevonedistat,</cell><cell>MICB</cell><cell>Neddylation</cell><cell>Advanced Solid Tumors</cell><cell>PR:14%[138]</cell><cell>NCT03057366</cell></row><row><cell>Docetaxel</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Phase 1</cell></row><row><cell>Pevonedistat, Ibrutinib</cell><cell>MICB</cell><cell>Neddylation</cell><cell>Relapsed or Refractory CLL or NHL</cell><cell>/</cell><cell>NCT03479268</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Phase 1</cell></row><row><cell>Pevonedistat, carboplatin</cell><cell>MICB</cell><cell>Neddylation</cell><cell>Advanced ICC</cell><cell>/</cell><cell>NCT04175912</cell></row><row><cell>and paclitaxel</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Phase 1</cell></row><row><cell>Pevonedistat, capecitabine</cell><cell>MICB</cell><cell>Neddylation</cell><cell>Advanced gastric cancer refractory to platinum</cell><cell>/</cell><cell>jRCT2031190020</cell></row><row><cell>plus oxaliplatin</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Pevonedistat,</cell><cell>MICB</cell><cell>Neddylation</cell><cell>MDS, CMML and AML</cell><cell>AZA alone VS Pevonedistat plus</cell><cell>NCT03268954</cell></row><row><cell>AZA</cell><cell></cell><cell></cell><cell></cell><cell>AZA: ORR(28% VS32%), OS(27.1</cell><cell>Phase 3</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>months VS 22.5 months) [141]</cell><cell></cell></row><row><cell>TAK-981, Rituximab</cell><cell>CD155</cell><cell>Sumoylation</cell><cell>Relapsed or Refractory CD20+NHL</cell><cell>/</cell><cell>NCT04074330</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Phase 1,2</cell></row><row><cell>TAK-981+</cell><cell>CD155</cell><cell>Sumoylation</cell><cell>Relapsed or Refractory MM</cell><cell>/</cell><cell>NCT04776018</cell></row><row><cell>Mezagitamab or</cell><cell>CD38</cell><cell></cell><cell></cell><cell></cell><cell>Phase 1,2</cell></row></table><note><p>(continued on next page)</p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1</head><label>1</label><figDesc>(continued )    </figDesc><table><row><cell>Drug</cell><cell>Target</cell><cell>PTM</cell><cell>Disease</cell><cell>Response Rate</cell><cell>Clinical trial No. &amp;</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Phase</cell></row><row><cell>Daratumumab and</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Hyaluronidase-fihj</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>TAK-981, Pembrolizumab</cell><cell>CD155</cell><cell>Sumoylation</cell><cell>Advanced or Metastatic Solid Tumors</cell><cell>/</cell><cell>NCT04381650</cell></row><row><cell></cell><cell>PD-1</cell><cell></cell><cell></cell><cell></cell><cell>Phase 1,2</cell></row><row><cell>TAK-981,</cell><cell>CD155</cell><cell>Sumoylation</cell><cell>HNSCC</cell><cell>/</cell><cell>NCT04065555</cell></row><row><cell>Cetuximab and Avelumab</cell><cell>EGFR</cell><cell></cell><cell></cell><cell></cell><cell>Phase 1,2</cell></row><row><cell></cell><cell>PD-L1</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>TAK-981</cell><cell>CD155</cell><cell>Sumoylation</cell><cell>Advanced Solid Tumors or Hematologic</cell><cell>/</cell><cell>NCT03648372</cell></row><row><cell></cell><cell></cell><cell></cell><cell>Malignancies</cell><cell></cell><cell>Phase 1,2</cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div><head>Acknowledgements</head><p>Not applicable.</p></div>
			</div>
			<div type="funding">
<div><head>Funding</head><p>This work was supported partially by grants from the <rs type="funder">National Natural Science Foundation of China, China</rs> (<rs type="grantNumber">82303069</rs>, <rs type="grantNumber">52102276</rs>, <rs type="grantNumber">82303126</rs>), the <rs type="funder">Natural Science Foundation of Fujian Province, China</rs> (<rs type="grantNumber">2023J05038</rs>), the <rs type="funder">Fujian Provincial Project of Education and Science for Young and Middle-aged Teachers, China</rs> (<rs type="grantNumber">JAT220076</rs>) and <rs type="funder">Startup Foundation of Fujian Medical University, China</rs> (<rs type="grantNumber">2022QH1003</rs>, <rs type="grantNumber">2022QH1783</rs>).</p></div>
<div><head>CRediT authorship contribution statement</head><p>Jie Wang: Writingoriginal draft, Visualization, Funding acquisition, Conceptualization. Yian Wang: Resources, Investigation. Xianjie Jiang: Resources, Investigation. Meifang Xu: <rs type="person">Resources. Meifeng Wang</rs>: <rs type="person">Resources. Rong Wang</rs>: <rs type="person">Visualization. Boshu Zheng</rs>: <rs type="person">Resources. Mingfen Chen</rs>: <rs type="person">Resources. Qi Ke</rs>: <rs type="person">Resources. Jun Long: Supervision</rs>, Writingreview &amp; editing, Funding acquisition.</p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_fVynwaq">
					<idno type="grant-number">82303069</idno>
				</org>
				<org type="funding" xml:id="_AZwAXnS">
					<idno type="grant-number">52102276</idno>
				</org>
				<org type="funding" xml:id="_xp5QW64">
					<idno type="grant-number">82303126</idno>
				</org>
				<org type="funding" xml:id="_W7ubU4a">
					<idno type="grant-number">2023J05038</idno>
				</org>
				<org type="funding" xml:id="_CNBsnav">
					<idno type="grant-number">JAT220076</idno>
				</org>
				<org type="funding" xml:id="_wGkMrvX">
					<idno type="grant-number">2022QH1003</idno>
				</org>
				<org type="funding" xml:id="_CjdBNPE">
					<idno type="grant-number">2022QH1783</idno>
				</org>
			</listOrg>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Declaration of competing interest</head><p>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. </p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Next generation of immune checkpoint inhibitors and beyond</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Marin-Acevedo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">O</forename><surname>Kimbrough</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Lou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Hematol. Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">45</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways</title>
		<author>
			<persName><forename type="first">L</forename><surname>Kraehenbuehl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Weng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Eghbali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Wolchok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Merghoub</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="37" to="50" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4</title>
		<author>
			<persName><forename type="first">S</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Luo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Cancer</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page">155</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape</title>
		<author>
			<persName><forename type="first">X</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Xiong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Xiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Xiong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zeng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol, Cancer</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page">10</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">The CD47-SIRPα immune checkpoint</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E W</forename><surname>Logtenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Scheeren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">N</forename><surname>Schumacher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="742" to="752" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Hallmarks of response, resistance, and toxicity to immune checkpoint blockade</title>
		<author>
			<persName><forename type="first">G</forename><surname>Morad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Helmink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Wargo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">184</biblScope>
			<biblScope unit="page" from="5309" to="5337" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints</title>
		<author>
			<persName><forename type="first">S</forename><surname>Koyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Akbay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Herter-Sprie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Buczkowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Richards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gandhi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Redig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Rodig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Asahina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Kulkarni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kuraguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Palakurthi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Fecci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Janne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Engelman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Gangadharan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Costa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Hammerman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Commun</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">10501</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">TIM3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients</title>
		<author>
			<persName><forename type="first">E</forename><surname>Limagne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Richard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Thibaudin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Fumet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Truntzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lagrange</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Favier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Coudert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ghiringhelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">OncoImmunology</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">1564505</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Breast cancer cells and PD-1/PD-L1 blockade upregulate the expression of PD-1, CTLA-4, TIM3 and LAG3 immune checkpoints in CD4 + T cells</title>
		<author>
			<persName><forename type="first">R</forename><surname>Saleh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Toor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Khalaf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Elkord</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccines</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">149</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">LAG3 and PD-1 blockade raises the bar for melanoma</title>
		<author>
			<persName><forename type="first">C</forename><surname>Robert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Can. (Ott.)</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="1251" to="1253" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Compensatory upregulation of PD-1, LAG3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Francois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Mcgray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Miliotto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Odunsi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">OncoImmunology</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">1249561</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Generation of TIM3 inhibitory single-domain antibodies to boost the antitumor activity of chimeric antigen receptor T cells</title>
		<author>
			<persName><forename type="first">L</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Zuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Feng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncol. Lett</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page">542</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Targeting TIM3 and PD-1 pathways to reverse T cell exhaustion and restore antitumor immunity</title>
		<author>
			<persName><forename type="first">K</forename><surname>Sakuishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Apetoh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Sullivan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Blazar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">K</forename><surname>Kuchroo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Anderson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Exp. Med</title>
		<imprint>
			<biblScope unit="volume">207</biblScope>
			<biblScope unit="page" from="2187" to="2194" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Blocking TIM3 in treatment-refractory advanced solid tumors: a phase ia/b study of LY3321367 with or without an anti-PD-L1 antibody</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Harding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Moreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Bang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Patnaik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Trigo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Szpurka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Doi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Calderon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Velez De Mendizabal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Calvo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gandhi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">T</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">R</forename><surname>Galvao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Leow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>De Miguel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="2168" to="2178" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Phase I/ib clinical trial of sabatolimab, an anti-TIM3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors</title>
		<author>
			<persName><forename type="first">G</forename><surname>Curigliano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Gelderblom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Mach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Doi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Tai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Forde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sarantopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Bedard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">S</forename><surname>Hodi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wilgenhof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Santoro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Sabatos-Peyton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Longmire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Xyrafas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gutzwiller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Manenti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Naing</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="3620" to="3629" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Immune inhibitory molecules LAG3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Woo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Turnis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Goldberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bankoti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Selby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Nirschl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Bettini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Gravano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Vogel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tangsombatvisit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Grosso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Netto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Smeltzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Utz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Workman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Pardoll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Korman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Drake</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Vignali</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="917" to="927" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Puhr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ilhan-Mutlu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">New emerging targets in cancer immunotherapy: the role of LAG3</title>
		<imprint>
			<date type="published" when="2019">2019</date>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">482</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma</title>
		<author>
			<persName><forename type="first">C</forename><surname>Brignone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Escudier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Grygar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Marcu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Triebel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="6225" to="6231" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Phase 1 trial of TIM3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Falchook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ribas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Davar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Eroglu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Luke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Hamilton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Pace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ghosh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dhar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Borgovan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Waszak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lorusso</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page">2504</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">The introduction of LAG3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">Y</forename><surname>Kreidieh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Tawbi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ther. Adv. Med. Oncol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">17588359231186027</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Sirpα on tumor-associated myeloid cells restrains antitumor immunity in colorectal cancer independent of its interaction with CD47</title>
		<author>
			<persName><forename type="first">C</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Liao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Yi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Jin</surname></persName>
		</author>
		<idno type="DOI">10.1038/s43018-023-00691-z</idno>
		<ptr target="https://doi.org/10.1038/s43018-023-00691-z" />
	</analytic>
	<monogr>
		<title level="j">Nat. Can. (Ott.)</title>
		<imprint>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Inhibition of the CD47-SIRPα axis for cancer therapy: a systematic review and meta-analysis of emerging clinical data</title>
		<author>
			<persName><forename type="first">J</forename><surname>Son</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Hsieh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Krause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Biter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Welsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Curran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Hong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Front. Immunol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">1027235</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">TIM3 restrains antitumour immunity by regulating inflammasome activation</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">O</forename><surname>Dixon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tabaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Schramm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Dionne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Rozenblatt-Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Regev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">K</forename><surname>Kuchroo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">595</biblScope>
			<biblScope unit="page" from="101" to="106" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">The inhibitory receptor TIM3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake</title>
		<author>
			<persName><forename type="first">Á</forename><surname>De Mingo Pulido</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hänggi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Celias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gardner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Batista-Bittencourt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mohamed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Trillo-Tinoco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Osunmakinde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Peña</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Onimus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kaisho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kaufmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mceachern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Soliman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">C</forename><surname>Luca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ruffell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="1154" to="1167" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<author>
			<persName><forename type="first">C</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schubart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Xiong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Imitola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Khoury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">X</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">B</forename><surname>Strom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">K</forename><surname>Kuchroo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">The TIM3 ligand galectin-9 negatively regulates T helper type 1 immunity</title>
		<imprint>
			<date type="published" when="2005">2005</date>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="1245" to="1252" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">CEACAM1 regulates TIM3-mediated tolerance and exhaustion</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kondo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gandhi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Dougan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Petersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Melum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pertel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Clayton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Raab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Beauchemin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Yazaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pyzik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Ostrowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Glickman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Rudd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Ploegh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Blumberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">517</biblScope>
			<biblScope unit="page" from="386" to="390" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">T cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse, disrupts stable synapse formation, and associates with receptor phosphatases</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Clayton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Haaland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Douglas-Vail</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mujib</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Chew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Ndhlovu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Ostrowski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunol</title>
		<imprint>
			<biblScope unit="volume">192</biblScope>
			<biblScope unit="page" from="782" to="791" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">The costimulatory activity of TIM3 requires Akt and MAPK signaling and its recruitment to the immune synapse</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kataoka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Manandhar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Workman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Banerjee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Szymczak-Workman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kvorjak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lohmueller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>Kane</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci. Signal</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">717</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Bat3 promotes T cell responses and autoimmunity by repressing TIM3-mediated cell death and exhaustion</title>
		<author>
			<persName><forename type="first">M</forename><surname>Rangachari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sakuishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Karman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Angin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wakeham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Greenfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Sobel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Okada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Mckinnon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Mak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Addo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">K</forename><surname>Kuchroo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Med</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1394" to="1400" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">TIM3 adaptor protein Bat3 is a molecular checkpoint of T cell terminal differentiation and exhaustion</title>
		<author>
			<persName><forename type="first">C</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">O</forename><surname>Dixon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Newcomer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zaghouani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Schramm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Goto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Christian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rangachari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Rosenblatt-Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Okada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Singer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Regev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Kuchroo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci. Adv</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">2710</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Sanmamed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Datar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">T</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Badri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Boto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sznol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Melero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A A</forename><surname>Vignali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Schalper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="334" to="347" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Posttranslational modifications of PD-L1 and their applications in cancer therapy</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Hung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="6349" to="6353" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Strategies for developing PD-1 inhibitors and future directions</title>
		<author>
			<persName><forename type="first">W</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">202</biblScope>
			<biblScope unit="page">115113</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Shao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genes Dis</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="848" to="863" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Phosphorylation: a fast switch for checkpoint signaling</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Xu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv. Exp. Med. Biol</title>
		<imprint>
			<biblScope unit="volume">1248</biblScope>
			<biblScope unit="page" from="347" to="398" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Global view of human protein glycosylation pathways and functions</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Schjoldager</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Narimatsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Joshi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Clausen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Mol. Cell Biol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="729" to="749" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">The humanization of N-glycosylation pathways in yeast</title>
		<author>
			<persName><forename type="first">S</forename><surname>Wildt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">U</forename><surname>Gerngross</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Microbiol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="119" to="128" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Protein glycosylation in gastric and colorectal cancers: toward cancer detection and targeted therapeutics</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Ferreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Magalhães</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gomes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Peixoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gaiteiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Fernandes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Reis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Lett</title>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Glycosylation in cancer: mechanisms and clinical implications</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Pinho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Reis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Cancer</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="540" to="555" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Oxidative phosphorylation as an emerging target in cancer therapy</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Ashton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Mckenna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Kunz-Schughart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Higgins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="2482" to="2490" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Phosphorylation: implications in cancer</title>
		<author>
			<persName><forename type="first">V</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Prasad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Roy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Singh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Protein J</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="1" to="6" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">The role of ubiquitination in tumorigenesis and targeted drug discovery</title>
		<author>
			<persName><forename type="first">L</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Meng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Signal Transduct</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">11</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note>Target Ther</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">The role of conformational dynamics in the recognition and regulation of ubiquitination</title>
		<author>
			<persName><forename type="first">D</forename><surname>Khago</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">J</forename><surname>Fucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Byrd</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Molecules</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page">5933</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">The next frontier: translational development of ubiquitination, SUMOylation, and NEDDylation in cancer</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Pellegrino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Guven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kasture</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Nastke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thakurta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gesta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">K</forename><surname>Vishnudas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">R</forename><surname>Narain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Kiebish</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int. J. Mol. Sci</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page">3480</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<author>
			<persName><forename type="first">M</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Fan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">SUMOylation homeostasis in tumorigenesis</title>
		<imprint>
			<date type="published" when="2020">2020</date>
			<biblScope unit="volume">469</biblScope>
			<biblScope unit="page" from="301" to="309" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein</title>
		<author>
			<persName><forename type="first">T</forename><surname>Kamitani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Yeh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Biol. Chem</title>
		<imprint>
			<biblScope unit="volume">272</biblScope>
			<biblScope unit="page" from="28557" to="28562" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">The balance between mono-and NEDD8-chains controlled by NEDP1 upon DNA damage is a regulatory module of the HSP70 ATPase activity</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Bailly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Perrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Serrano-Macia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Maghames</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Leidecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Trauchessec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Martinez-Chantar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gartner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Xirodimas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Rep</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="212" to="224" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Protein neddylation: beyond cullin-RING ligases</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">I</forename><surname>Enchev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Schulman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Peter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Mol. Cell Biol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="30" to="44" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<author>
			<persName><forename type="first">H</forename><surname>Wada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Caskey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Yeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kamitani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Cleavage of the C-terminus of NEDD8 by UCH-L3</title>
		<imprint>
			<date type="published" when="1998">1998</date>
			<biblScope unit="page" from="688" to="692" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">NEDD8 nucleates a multivalent cullin-RING-UBE2D ubiquitin ligation assembly</title>
		<author>
			<persName><forename type="first">K</forename><surname>Baek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Krist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Prabu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Klügel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Neumaier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gronau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kleiger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Schulman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">578</biblScope>
			<biblScope unit="page" from="461" to="466" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma</title>
		<author>
			<persName><forename type="first">S</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int. J. Cancer</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="page" from="763" to="774" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">K6-linked SUMOylation of BAF regulates nuclear integrity and DNA replication in mammalian cells</title>
		<author>
			<persName><forename type="first">Q</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl. Acad. Sci. U.S.A</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="10378" to="10387" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Neddylation of PTEN regulates its nuclear import and promotes tumor development</title>
		<author>
			<persName><forename type="first">P</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Res</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="291" to="311" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Palmitoylation as a signal for delivery</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Xu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv. Exp. Med. Biol</title>
		<imprint>
			<biblScope unit="volume">1248</biblScope>
			<biblScope unit="page" from="399" to="424" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Protein palmitoylation and cancer</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Dixon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">EMBO Rep</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page">46666</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Protein S-palmitoylation in immunity</title>
		<author>
			<persName><forename type="first">T</forename><surname>Das</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Yount</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Hang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Open Biol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<date type="published" when="2021">2021. 200411</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">SheddomeDB 2023: a revision of an ectodomain shedding database based on a comprehensive literature review and online Resources</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Wu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Proteome Res</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="2570" to="2576" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">NKG2D and MICA/B shedding: a &apos;tag game&apos; between NK cells and malignant cells</title>
		<author>
			<persName><forename type="first">S</forename><surname>Xing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ferrari De Andrade</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Transl. Immunology</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">1230</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">TIM3 in normal and malignant hematopoiesis: structure, function, and signaling pathways</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Kikushige</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Sci</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="3419" to="3426" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<author>
			<persName><forename type="first">E</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">A</forename><surname>Ramagopal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mukhopadhaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fedorov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Fedorov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Zencheck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Lary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Cole</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Dilorenzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Allison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Nathenson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Almo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface</title>
		<imprint>
			<date type="published" when="2007">2007</date>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="311" to="321" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Van De Weyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Muehlfeit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Klose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Bonventre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Walz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Kuehn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">A highly conserved tyrosine of TIM3 is phosphorylated upon stimulation by its ligand galectin-9</title>
		<imprint>
			<date type="published" when="2006">2006</date>
			<biblScope unit="volume">351</biblScope>
			<biblScope unit="page" from="571" to="576" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">TIM3 promotes tumorpromoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis</title>
		<author>
			<persName><forename type="first">X</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Han</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">OncoImmunology</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">1211219</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Negative regulation of Nod-like receptor protein 3 inflammasome activation by T cell Ig mucin-3 protects against peritonitis</title>
		<author>
			<persName><forename type="first">W</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Han</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunology</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page" from="71" to="83" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Tumor-infiltrating DCs suppress nucleic acidmediated innate immune responses through interactions between the receptor TIM3 and the alarmin HMGB1</title>
		<author>
			<persName><forename type="first">S</forename><surname>Chiba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baghdadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Akiba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yoshiyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kinoshita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dosaka-Akita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Fujioka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ohba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Gorman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Colgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hirashima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Uede</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Takaoka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yagita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jinushi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Immunol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="832" to="842" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Protein and lipid motifs regulate phosphatidylserine traffic in yeast</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Voelker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Soc. Trans</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1141" to="1145" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Phosphatidylserine transport to the mitochondria is regulated by ubiquitination</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Schumacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Voelker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Biol. Chem</title>
		<imprint>
			<biblScope unit="volume">277</biblScope>
			<biblScope unit="page" from="51033" to="51042" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">A disintegrin and metalloprotease (ADAM) 10 and ADAM17 are major sheddases of T cell immunoglobulin and mucin domain 3 (TIM3)</title>
		<author>
			<persName><forename type="first">K</forename><surname>Möller-Hackbarth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dewitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Schweigert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Trad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Garbers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rose-John</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Scheller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Biol. Chem</title>
		<imprint>
			<biblScope unit="volume">288</biblScope>
			<biblScope unit="page" from="34529" to="34544" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">LAG3: from molecular functions to clinical applications</title>
		<author>
			<persName><forename type="first">T</forename><surname>Maruhashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sugiura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Okazaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Okazaki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunother. Cancer</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">1014</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">LAG3, a novel lymphocyte activation gene closely related to CD4</title>
		<author>
			<persName><forename type="first">F</forename><surname>Triebel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jitsukawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Baixeras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Roman-Roman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Genevee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Viegas-Pequignot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hercend</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Exp. Med</title>
		<imprint>
			<biblScope unit="volume">171</biblScope>
			<biblScope unit="page" from="1393" to="1405" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Biochemical analysis of the regulatory T cell protein lymphocyte activation gene-3 (LAG3; CD223)</title>
		<author>
			<persName><forename type="first">N</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Workman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Vignali</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunol</title>
		<imprint>
			<biblScope unit="volume">173</biblScope>
			<biblScope unit="page" from="6806" to="6812" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Metalloproteases regulate T-cell proliferation and effector function via LAG3</title>
		<author>
			<persName><forename type="first">N</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Forbes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Vignali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Heale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Saftig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hartmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Black</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Blobel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Dempsey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Workman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Vignali</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">EMBO J</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="494" to="504" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Workman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dugger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Vignali</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunol</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="page" from="5392" to="5395" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">The CD4-related molecule, LAG3 (CD223), regulates the expansion of activated T cells</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Workman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Vignali</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Immunol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="970" to="979" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">MARCH ligases in immunity</title>
		<author>
			<persName><forename type="first">H</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Mintern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Villadangos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr. Opin. Immunol</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="38" to="43" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Ubiquitin ligase MARCH 8 cooperates with CD83 to control surface MHC II expression in thymic epithelium and CD4 T cell selection</title>
		<author>
			<persName><forename type="first">H</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Guan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Vuong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ishido</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>La Gruta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Villadangos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Mintern</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Exp. Med</title>
		<imprint>
			<biblScope unit="volume">213</biblScope>
			<biblScope unit="page" from="1695" to="1703" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">The tumour suppressor TMEM127 is a nedd4-family E3 ligase adaptor required by Salmonella SteD to ubiquitinate and degrade MHC class II molecules</title>
		<author>
			<persName><forename type="first">E</forename><surname>Alix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Godlee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Cerny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Blundell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Tocci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Matthews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Pruneda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">N</forename><surname>Swatek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Komander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sleap</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Holden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Host Microbe</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="54" to="68" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells</title>
		<author>
			<persName><forename type="first">X</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Harden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Gonzalez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Francesco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Chiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Irving</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Tom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ivelja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Refino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Eaton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Grogan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Immunol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="48" to="57" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy</title>
		<author>
			<persName><forename type="first">B</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Exp. Clin. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page">267</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<author>
			<persName><forename type="first">R</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Mo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Xiong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">CD155 and its receptors in cancer immune escape and immunotherapy</title>
		<imprint>
			<date type="published" when="2023">2023</date>
			<biblScope unit="volume">573</biblScope>
			<biblScope unit="page">216381</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses</title>
		<author>
			<persName><forename type="first">A</forename><surname>Shibuya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Shibuya</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int. Immunol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="687" to="692" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8 + T cells</title>
		<author>
			<persName><forename type="first">M</forename><surname>Braun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Aguilera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sundarrajan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Corvino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stannard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Krumeich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Das</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Lima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Meza Guzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Salim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Jorge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Vari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lepletier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Raghavendra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pearson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Madore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Bald</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">immunity</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="805" to="823" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Requirement of the serine at residue 329 for lipid raft recruitment of DNAM-1 (CD226)</title>
		<author>
			<persName><forename type="first">J</forename><surname>Shirakawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Shibuya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Shibuya</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int. Immunol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="217" to="223" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">DNAM-1 controls NK cell activation via an ITT-like motif</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Davidson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Colonna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Veillette</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Exp. Med</title>
		<imprint>
			<biblScope unit="volume">212</biblScope>
			<biblScope unit="page" from="2165" to="2182" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells</title>
		<author>
			<persName><forename type="first">S</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Fan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Death Differ</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="456" to="464" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Johnston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Comps-Agrar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hackney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Huseni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Javinal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Chiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Irving</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Eaton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Grogan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="923" to="937" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Protein kinase C is involved in the regulation of both signaling and adhesion mediated by DNAX accessory molecule-1 receptor</title>
		<author>
			<persName><forename type="first">A</forename><surname>Shibuya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Lanier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Phillips</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunol</title>
		<imprint>
			<biblScope unit="volume">161</biblScope>
			<biblScope unit="page" from="1671" to="1676" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation</title>
		<author>
			<persName><forename type="first">K</forename><surname>Shibuya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shirakawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kameyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Honda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tahara-Hanaoka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Miyamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Onodera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sumida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nakauchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Miyoshi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Shibuya</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Exp. Med</title>
		<imprint>
			<biblScope unit="volume">226</biblScope>
			<biblScope unit="page" from="1829" to="1839" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>CD</note>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8+ T cell dysfunction and maintain memory phenotype</title>
		<author>
			<persName><forename type="first">B</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Jankovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Golubov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Poon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Oswald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ramos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Waite</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Adler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Macdonald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Rowlands</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Brydges</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Siao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Poueymirou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Macdonald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Skokos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci Immunol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">7061</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cells</title>
		<author>
			<persName><forename type="first">M</forename><surname>Braun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Aguilera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sundarrajan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Corvino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stannard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Krumeich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Das</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Lima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Meza Guzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Salim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Jorge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Vari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lepletier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Raghavendra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pearson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Madore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Bald</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="805" to="823" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Ligand stimulation of CD155alpha inhibits cell adhesion and enhances cell migration in fibroblasts</title>
		<author>
			<persName><forename type="first">T</forename><surname>Oda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ohka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nomoto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Biophys. Res. Commun</title>
		<imprint>
			<biblScope unit="volume">319</biblScope>
			<biblScope unit="page" from="1253" to="1264" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">UPR decreases CD226 ligand CD155 expression and sensitivity to NK cell-mediated cytotoxicity in hepatoma cells</title>
		<author>
			<persName><forename type="first">J</forename><surname>Gong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Xing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Zhuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Immunol</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="3758" to="3767" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Plasma membrane profiling defines an expanded class of cell surface proteins selectively targeted for degradation by HCMV US2 in cooperation with UL141</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Van Den Boomen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tomasec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Weekes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Antrobus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Stanton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ruckova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sugrue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Wilkie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Davison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Wilkinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Lehner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Pathog</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">1004811</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells</title>
		<author>
			<persName><forename type="first">B</forename><surname>Zitti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Molfetta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fionda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Quatrini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Stabile</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lecce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>De Turris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Ricciardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Petrucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cippitelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gismondi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Santoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Paolini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci. Rep</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">10445</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">SUMOylation and related posttranslational modifications in natural killer cell anti-cancer responses</title>
		<author>
			<persName><forename type="first">R</forename><surname>Molfetta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Petillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cippitelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Paolini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Front. Cell Dev. Biol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">1213114</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">KIR receptors as key regulators of NK cells activity in health and disease</title>
		<author>
			<persName><forename type="first">J</forename><surname>Dębska-Zielkowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Moszkowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zieliński</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zielińska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dukat-Mazurek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Trzonkowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stefańska</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cells</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">1777</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Targeting the ubiquitination/deubiquitination process to regulate immune checkpoint pathways</title>
		<author>
			<persName><forename type="first">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Song</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Signal Transduct. Targeted Ther</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">28</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">Identifying the ERAD ubiquitin E3 ligases for viral and cellular targeting of MHC class I</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Van Den Boomen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Lehner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Immunol</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="106" to="111" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Recent advances in molecular mechanisms of the NKG2D pathway in hepatocellular carcinoma</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biomolecules</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">301</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Leveraging NKG2D ligands in immunooncology</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Fuertes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">I</forename><surname>Domaica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">W</forename><surname>Zwirner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Front. Immunol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">713158</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastomainitiating cells</title>
		<author>
			<persName><forename type="first">F</forename><surname>Wolpert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Tritschler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Steinle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Eisele</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="382" to="391" />
			<date type="published" when="2014">2014</date>
			<pubPlace>Neuro</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: association with soluble MICA shedding</title>
		<author>
			<persName><forename type="first">L</forename><surname>Huergo-Zapico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Gonzalez-Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Contesti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gonzalez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>López-Soto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fernandez-Guizan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Acebes-Huerta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>De Los Toyos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lopez-Larrea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Groh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Spies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gonzalez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Immunol</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="1201" to="1210" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>Immunotherapy</note>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">Palmitoylation of MICA, a ligand for NKG2D, mediates its recruitment to membrane microdomains and promotes its shedding</title>
		<author>
			<persName><forename type="first">S</forename><surname>Agüera-González</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Gross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fernández-Messina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Ashiru</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Esteso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Hang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">T</forename><surname>Reyburn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">O</forename><surname>Long</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Valés-Gómez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Immunol</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="3667" to="3676" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">Inhibition of asparagine-linked glycosylation participates in hypoxia-induced down-regulation of cell-surface MICA expression</title>
		<author>
			<persName><forename type="first">N</forename><surname>Yamada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kato-Kogoe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yamanegi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nishiura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Fujihara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fukunishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Okamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Terada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nakasho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anticancer Res</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="1353" to="1359" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">2-deoxy D-glucose prevents cell surface expression of NKG2D ligands through inhibition of N-linked glycosylation</title>
		<author>
			<persName><forename type="first">L</forename><surname>Andresen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Skovbakke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Persson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hagemann-Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Hansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Skov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunol</title>
		<imprint>
			<biblScope unit="volume">188</biblScope>
			<biblScope unit="page" from="1847" to="1855" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">c-Cbl regulates MICA-but not ULBP2induced NKG2D down-modulation in human NK cells</title>
		<author>
			<persName><forename type="first">R</forename><surname>Molfetta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Quatrini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Capuano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gasparrini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zitti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zingoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Galandrini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Santoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Paolini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Immunol</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="2761" to="2770" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Histamine reduces susceptibility to natural killer cells via down-regulation of NKG2D ligands on human monocytic leukaemia THP-1 cells</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Nagai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kuroishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Endo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sugawara</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunology</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page" from="103" to="114" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Barclay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Van Den</surname></persName>
		</author>
		<author>
			<persName><surname>Berg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annu. Rev. Immunol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="25" to="50" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">SIRPα sequesters SHP-2 to promote IL-4 and IL-13 signaling and the alternative activation of macrophages</title>
		<author>
			<persName><forename type="first">L</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kidder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Bian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K T</forename><surname>Chiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ouellette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci. Signal</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">3966</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">EGFR-induced and c-src-mediated CD47 phosphorylation inhibits TRIM21-dependent polyubiquitylation and degradation of CD47 to promote tumor immune evasion</title>
		<author>
			<persName><forename type="first">L</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Meng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lyu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv. Sci</title>
		<imprint>
			<biblScope unit="page">2206380</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">Coinhibitory pathways in the B7-CD28 ligand-receptor family</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Schildberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Freeman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Sharpe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="955" to="972" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">B7-H4, a promising target for immunotherapy</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">P</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell. Immunol</title>
		<imprint>
			<biblScope unit="volume">347</biblScope>
			<biblScope unit="page">104008</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">Pharmacologic suppression of B7-H4 glycosylation restores antitumor immunity in immune-cold breast cancers</title>
		<author>
			<persName><forename type="first">X</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Bahar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Kepp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Hung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kroemer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Discov</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="1872" to="1893" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b112">
	<monogr>
		<title level="m" type="main">B7 family protein glycosylation: promising novel targets in tumor treatment</title>
		<author>
			<persName><forename type="first">L</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Guan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Xiang</surname></persName>
		</author>
		<idno type="DOI">10.3389/fimmu.2022.1088560</idno>
		<ptr target="https://doi.org/10.3389/fimmu.2022.1088560" />
		<imprint>
			<date type="published" when="2022">2022</date>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">1088560</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30</title>
		<author>
			<persName><forename type="first">E</forename><surname>Schlecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Fiegler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Arnold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Altevogt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rose-John</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Moldenhauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sucker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Paschen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Von Strandmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Textor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cerwenka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="3429" to="3440" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main">Nonfucosylation of an anti-TIGIT antibody enhances FcγR engagement, driving innate immune activation and antitumor activity</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Thurman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Grogan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lucas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gutierrez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Heiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Wo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Blackmarr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Peterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Gardai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Front. Immunol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">1280986</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main">Natural killer cell-mediated shedding of ULBP2</title>
		<author>
			<persName><forename type="first">R</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Sun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">91133</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main">ADAM protease inhibition overcomes resistance of breast cancer stem-like cells to γδ T cell immunotherapy</title>
		<author>
			<persName><forename type="first">I</forename><surname>Dutta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Dieters-Castator</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Papatzimas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Medina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schueler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Derksen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lajoie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Postovit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Siegers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Lett</title>
		<imprint>
			<biblScope unit="volume">496</biblScope>
			<biblScope unit="page" from="156" to="168" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main">The fatty-acid amide hydrolase inhibitor URB597 inhibits MICA/B shedding</title>
		<author>
			<persName><forename type="first">K</forename><surname>Sekiba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Otsuka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Seimiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Funato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Miyakawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Koike</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci. Rep</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">15556</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main">Potential for enhanced therapeutic activity of biological cancer therapies with doxycycline combination</title>
		<author>
			<persName><forename type="first">H</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sampath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Thorne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gene Ther</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="770" to="778" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b119">
	<analytic>
		<title level="a" type="main">Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNγ production by human NK cells in the presence of antibody-bound tumor cells</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Mishra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Pore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>Michelotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Walcheck</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Immunol, Immunotherapy</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="1407" to="1416" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main">Nonblocking monoclonal antibody targeting soluble MIC revamps endogenous innate and adaptive antitumor responses and eliminates primary and metastatic tumors</title>
		<author>
			<persName><forename type="first">S</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">F</forename><surname>Staveley-O'carroll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Wu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="4819" to="4830" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main">Tumor-derived NKG2D ligand sMIC reprograms NK cells to an inflammatory phenotype through CBM signalosome activation</title>
		<author>
			<persName><forename type="first">P</forename><surname>Dhar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Basher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Ji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Wainwright</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hagler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mackay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Wu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Commun. Biol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">905</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main">MICA/B-targeted antibody promotes NK cell-driven tumor immunity in patients with intrahepatic cholangiocarcinoma</title>
		<author>
			<persName><forename type="first">B</forename><surname>Oliviero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Varchetta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Pessino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Maiello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Falleni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Tosi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Donadon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Soldani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Franceschini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Torzilli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Piccolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Barabino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Opocher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maestri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bernuzzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Wucherpfennig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">U</forename><surname>Mondelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mantovani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">OncoImmunology</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">2035919</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main">MICA/B antibody induces macrophage-mediated immunity against acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Alves Da Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Xing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Kotini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Papapetrou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Wucherpfennig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mascarenhas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ferrari De Andrade</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="205" to="216" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b124">
	<analytic>
		<title level="a" type="main">Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein</title>
		<author>
			<persName><forename type="first">N</forename><surname>Torres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Regge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Secchiari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Friedrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Spallanzani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">L</forename><surname>Raffo Iraolagoitia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Núñez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Sierra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ziblat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Santilli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Gilio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Almada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lauche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pardo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">I</forename><surname>Domaica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Fuertes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Madauss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Hance</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">S</forename><surname>Gloger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Zylberman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">W</forename><surname>Zwirner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunother. Cancer</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">233</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b125">
	<analytic>
		<title level="a" type="main">Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Salih</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Antropius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gieseke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Z</forename><surname>Lutz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kanz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Rammensee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Steinle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="1389" to="1396" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main">Broad tumorassociated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB</title>
		<author>
			<persName><forename type="first">V</forename><surname>Groh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Rhinehart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Secrist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Grabstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Spies</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl. Acad. Sci. U.S.A</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="6879" to="6884" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b127">
	<analytic>
		<title level="a" type="main">Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3</title>
		<author>
			<persName><forename type="first">C</forename><surname>Fionda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Malgarini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Soriani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zingoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cecere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Iannitto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Ricciardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Federico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Petrucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Santoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cippitelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunol</title>
		<imprint>
			<biblScope unit="volume">190</biblScope>
			<biblScope unit="page" from="6662" to="6672" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b128">
	<analytic>
		<title level="a" type="main">A soluble LAG3 protein as an immunopotentiator for therapeutic vaccines: preclinical evaluation of IMP321</title>
		<author>
			<persName><forename type="first">S</forename><surname>Fougeray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Brignone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Triebel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="5426" to="5433" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b129">
	<analytic>
		<title level="a" type="main">First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG3Ig) enhances immune responses and antitumor activity</title>
		<author>
			<persName><forename type="first">C</forename><surname>Fionda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Malgarini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Soriani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zingoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cecere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Iannitto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Ricciardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Federico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Petrucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Santoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cippitelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Transl. Med</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">71</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b130">
	<analytic>
		<title level="a" type="main">A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma</title>
		<author>
			<persName><forename type="first">C</forename><surname>Brignone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Escudier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Grygar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Marcu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Triebel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="6225" to="6231" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b131">
	<analytic>
		<title level="a" type="main">Vaccination with LAG3Ig (IMP321) and peptides induces specific CD4 and CD8 Tcell responses in metastatic melanoma patients-report of a phase I/IIa clinical trial</title>
		<author>
			<persName><forename type="first">A</forename><surname>Legat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Maby-El Hajjami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Baumgaertner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cagnon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Maillard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Geldhof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Iancu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lebon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Guillaume</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Dojcinovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Michielin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Romano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Berthod</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rimoldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Triebel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Luescher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Rufer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Speiser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1330" to="1340" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b132">
	<analytic>
		<title level="a" type="main">Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation</title>
		<author>
			<persName><forename type="first">C</forename><surname>Fionda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Soriani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Malgarini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Iannitto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Santoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cippitelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunol</title>
		<imprint>
			<biblScope unit="volume">183</biblScope>
			<biblScope unit="page" from="4385" to="4394" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b133">
	<analytic>
		<title level="a" type="main">Small-molecule PROTACs for cancer immunotherapy</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Kang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Molecules</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page">5439</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b134">
	<analytic>
		<title level="a" type="main">Checkpoint nano-PROTACs for activatable cancer photo-immunotherapy</title>
		<author>
			<persName><forename type="first">C</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Pu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv. Mater</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page">2208553</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b135">
	<analytic>
		<title level="a" type="main">Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition</title>
		<author>
			<persName><forename type="first">S</forename><surname>Petillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Capuano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Molfetta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fionda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mekhloufi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pighi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Antonangeli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zingoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Soriani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Petrucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Galandrini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Paolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Santoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cippitelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Death Dis</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">836</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b136">
	<analytic>
		<title level="a" type="main">Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Lockhart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Bauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Aggarwal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Harvey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sedarati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Nip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Faessel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Dash</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Dezube</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">V</forename><surname>Faller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dowlati</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Invest. N. Drugs</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="87" to="97" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b137">
	<analytic>
		<title level="a" type="main">Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8activating enzyme inhibitor in patients with advanced solid tumors</title>
		<author>
			<persName><forename type="first">X</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sedarati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">V</forename><surname>Faller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Faessel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chowdhury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bolleddula</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Venkatakrishnan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Papai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Invest. N. Drugs</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="488" to="498" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b138">
	<analytic>
		<title level="a" type="main">Pevonedistat, a firstin-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Swords</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Coutre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Maris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Zeidner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Foran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cruz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Erba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Berdeja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Tam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Vardhanabhuti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Pawlikowska-Dobler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Faessel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Dash</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sedarati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Dezube</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">V</forename><surname>Faller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Savona</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="page" from="1415" to="1424" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b139">
	<analytic>
		<title level="a" type="main">Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Swords</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Erba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Deangelo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Bixby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Hua</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Blakemore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Faessel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sedarati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Dezube</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Giles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Medeiros</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br. J. Haematol</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="page" from="534" to="543" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b140">
	<analytic>
		<title level="a" type="main">The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype? Ther</title>
		<author>
			<persName><forename type="first">A</forename><surname>Snow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Zeidner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv. Hematol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">20406207221112899</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b141">
	<analytic>
		<title level="a" type="main">Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J A</forename><surname>Schoonderwoerd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Kroonen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">J</forename><surname>De Graaf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sluijter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ruano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>González-Prieto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Verlaan-De Vries</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Arens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">F C C</forename><surname>De Miranda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J A C</forename><surname>Hawinkels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Van Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C O</forename><surname>Vertegaal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gut</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="2266" to="2283" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b142">
	<analytic>
		<title level="a" type="main">SUMOylation inhibitors activate anti-tumor immunity by reshaping the immune microenvironment in a preclinical model of hepatocellular carcinoma</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Qiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Tang</surname></persName>
		</author>
		<idno type="DOI">10.1007/s13402-023-00880-z</idno>
		<ptr target="https://doi.org/10.1007/s13402-023-00880-z" />
	</analytic>
	<monogr>
		<title level="j">Cell. Oncol</title>
		<imprint>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note>Advance online publication</note>
</biblStruct>

<biblStruct xml:id="b143">
	<analytic>
		<title level="a" type="main">The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nakamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Grossman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Xega</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cvet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Shapiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Huszar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="2770" to="2781" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b144">
	<analytic>
		<title level="a" type="main">A smallmolecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Lightcap</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Grossman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Khattar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Xega</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Gavin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Imaichi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Garnsey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Koenig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Milhollen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Hatton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Riceberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Shinde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Huszar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci. Transl. Med</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">7791</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
